AU603775B2

AU603775B2 – Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid
– Google Patents

AU603775B2 – Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid
– Google Patents
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

Download PDF
Info

Publication number
AU603775B2

AU603775B2
AU63512/86A
AU6351286A
AU603775B2
AU 603775 B2
AU603775 B2
AU 603775B2
AU 63512/86 A
AU63512/86 A
AU 63512/86A
AU 6351286 A
AU6351286 A
AU 6351286A
AU 603775 B2
AU603775 B2
AU 603775B2
Authority
AU
Australia
Prior art keywords
inhibin
chain
human
porcine
sequence
Prior art date
1985-10-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU63512/86A
Other versions

AU6351286A
(en

Inventor
Anthony John Mason
Peter Horst Seeburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genentech Inc

Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1985-10-03
Filing date
1986-10-02
Publication date
1990-11-29
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=27419805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU603775(B2)
“Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1986-09-12
Priority claimed from US06/906,729
external-priority
patent/US4798885A/en

1986-10-02
Application filed by Genentech Inc
filed
Critical
Genentech Inc

1987-04-09
Publication of AU6351286A
publication
Critical
patent/AU6351286A/en

1990-11-29
Application granted
granted
Critical

1990-11-29
Publication of AU603775B2
publication
Critical
patent/AU603775B2/en

2006-10-02
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/575—Hormones

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

Abstract

DNA encoding the prepro inhibin alpha and beta chains has been isolated. This DNA is ligated into expression vectors and used to transform host cells for the preparation of inhibin or activin. Also provided are prohormone domains and other inhibins alpha or beta chain derivatives having therapeutic or diagnostic interest. The compositions provided herein are useful in the manipulation of fertility in animals.

Description

‘I-
J
i i COMMONWEALTH OF AUSTRALIA PATENT ACT 1952 COMPLETE SPECIFICATION (Original) FOR OFFICE USE 6-351Iz8 Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority: Related Art: F~hi ~ocmer&~OftaT’n the1 -made uwie Se:tl:fl 49 and is correct fo It I e 049441
I
Name of Applicant: oQ os 0 0 Address of Applicant: 4*04 #0tt so «a a a e °0 Actual Inventor(s): 4444 GENENTECH, INC.
460 Point San Bruno Boulevard, South San Francisco, California 94080, United States of America.
Anthony John MASON Peter Horst SEEBURG 0 4 Address for Service: DAVIES COLLISON, Patent Attorneys, 1 Little Collins Street, Melbourne, 3000.
«o a 4*0 a D a o B O 0 00 Complete Specification for the invention entitled: “NUCLEIC ACID ENCODING THE a OR CHAINS OF INHIBIN AND METHOD FOR SYNTHESIZING POLYPEPTIDES USING SUCH NUCLEIC ACID” The following statement is a full description of this invention, including the best method of performing it known to us: -1- EXPRESS MAIL #B65030199 September 12, 1986 100/297P2 -la- NUCLEIC ACID ENCODING tHE a OR P CHAINS OF INHIBIN AND METHOD FOR SYNTHESIZING POLYPEPTIDES USING SUCH NUCLEIC ACID o 4 4 44 StO t I A I At
BACKGROUND
This invention relates to methods for making proteins in recombinant cell culture which contain the a or P chains of inhibin. In particular, it relates to methods for obtaining and using DNA which encodes inhibin, and for making inhibin variants that depart from the amino acid sequence of natural animal or human inhibins and the naturally-occurring alleles thereof.
Inhibin is a protein produced in the gonad which acts specifically at the pituitary level to inhibit the secretion of follicle-stimulating hormone (FSH). The existence of inhibin was first postulated by McCullagh in 1932 (“Science” 26: 19-20). Such preferential regulation of the gqnadotropin secretion has generated a great deal of interest and has prompted many laboratories in the past fifty years to attempt to isolate and characterize this substance from extracts of testis, spermatozoa, rete testis fluid, seminal plasma and ovarian follicular fluid, LC8x172.mdh using various bioassays. ‘Although many reports have appeared in the literature claiming the purification of inhibin-like material with molecular weights ranging from 5,000 to 100,000 daltons, subsequent studies have shown that these substances were not homogenous, did giot have the high specific activity expected of true inhibin and/or failed to exhibit the molecular characteristics of inhibin as described herein (de Jong, Inhibin- Factor Artifact, “Molecular Cellular Endocrin.” 13: 1-10 (1979); Sheth e ai., 1984, 11-15; Seidah et Al., 1984, 75(2):349-355; Lilja Vt aI., March 1985, 182(1):181-184; Li e aI., June 1985, “Proc. Nat. Acad.
Sci. USA” £2:4041-4044; Seidah ft Al., 1i67(l):98-102; and Beksac et al., 1984, “Intern. J. Andrology” 7:389-397).
A polypeptide having inhibin activity was purified from 0 bovine or ovine follicular fluid (PCT 86/00078, published January 4 09 *o 0 03, 1986). This protein was reported to have a molecular weight of 56,000±1,000 on SDS-PAGE and was dissociable into two subunits having apparent molecular weights of 44, 000+3,000 and 14,000±2,000. Amino terminal sequences for each subunit were described.
0 0 0 00 Two proteins both having a molecular weight of about 9. 9 9 32,000 daltons and having inhibin activity have been successfully 25 isolated from porcine follicular fluid. Purification of porcine inhibin to substantial homogeneity, about 90% by weight of t a total protein in the fraction, was achieved through a combination 0 of protein separation procedures including heparin-Sepharose affinity chromatography, gel filtration and reverse-phase, highperformance liquid chromatography (RP-HPLC).
These proteins were isolated to substantial homogeneity from material obtained from swine and are referred to as Protein A and Protein B. Each protein has a molecular weight of about 32,000 daltons (32K) and is composed of two polypeptide chains LC8x172.mdh -3xi having molecular weights of 18,000 and 14,000 daltons, respectively, the chains being linked together in the hormonallyactive protein by disulfide bonding. The amino-terminal amino acid residue sequence of the 18,000 dalton (18K) or alpha chain of I both proteins was determined to be Ser-Thr-Ala-Pro-Leu-Pro-Trp- Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu- Pro-Ala-Val. The amino-terminal amino acid residue sequence of the 14,000 dalton (14K) or beta chain of Protein A was determined to be Gly-Leu-Glu-X-Asp-Gly-Lys-Val-Asn-Ile-X-X-Lys-Lys-Gln-Phe- S0 Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala and of Protein B was determined to be Gly-Leu-Glu-X-Asp-Gly-Arg-Thr-Asn- Leu-X-X-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu. Proteins A and B have been completely charsa-terized. Each 32K protein exhibits inhibin activity in that it specifically inhibits the basal 15 secretion of FSH but does not inhibit secretion of luteinizing *o hormone The individual chains were not hormonally-active.
oa 4 After the filing of the parent application hereto, *inhibin B-chain dimers were shown to exist in follicular fluid as naturally-occurring substances, termed activin, which are capable Sof stimulating FSH release by rat anterior pituitary cells (Vale et a1., 1986, “Nature” 121:776-779 and Ling et al., 1986, “Nature” S21:779-782).
The amino acid sequence of the a and p chains of inhibin from humans remained unknown until the invention herein. The Slarge quantities of human follicular fluid required to parallel the studies conducted with animal inhibins are not readily available, nor is there any assurance that human and animal inhibins would be sufficiently similar that purification using a parallel procedure would be effective. Accordingly, methods are needed for determining the characteristics and amino acid sequence for human inhibin.
needed are economical methods for making the a and Also needed are economical methods for making the a and LC8xl72.mdh .I I, i r i: i P chains of inhibin in large quantities, preferably entirely and completely free of proteins from the species homologous to the inhibin in question, which inhibin preferably also is biologically active.
These and other objects will be apparent from consideration of the invention as a whole.
0 6 0 00 00 0 0 0 0 0 69 0 00 0 q 0000 *0 $r 0 0 Nucleic acid now has been isolated and cloned in replicable vectors which encodes the mature porcine and human a and f chains of inhibin and their precursor prepro and pro forms.
Sequencing of inhibin-encoding cDNA has led to the identification of prodomain regions located N-terminal to the mature inhibin chains that represent coordinately expressed biologically active polypeptides. The prodomain regions or prodomain immunogens are useful in monitoring preproinhibin processing in transformant cell culture or in experiments directed at modulating the clinical condition or reproductive physiology of animals. Thus a or chain nucleic acid is used to prepare prodomain sequences from the precursor forms of the inhibin chains, to transform host cells for the recombinant expression of mature inhibin a and/or P chains, and in diagnostic assays. In particular, regions from inhibin a and/or P chains are expressed in recombinant cell culture by a method comprising ligating the nucleic acid encoding the region into a replicable vector under the control of a promoter, transforming a host cell with the vector, culturing the host cell and recovering the prodomain, activin or inhibin from the cultured cell. Inhibin, activin and prodomains produced by the method of this invention are entirely free of homologous source proteins and can be produced in biologically active form.
The nucleic acids identified herein encode the a, PA and PB chains of porcine or human inhibin. Recombinant cells are LC8x172.mdh all tt~ transformed to express aPA or aPB inhibins, or to express #-chain heterodimers or homodimers (which are collectively referred to in the literature as activin). p-chain dimers as products of recombinant cell expression are free of homologous proteins with i which they ordinarily are associated in nature.
Inhibin or activin and their nontoxic salts, combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, are administered to mammals, including humans, for control of fertility. Administration of inhibin decreases fertility in female mammals and decreases spermatogenesis in male mammals, and administration of a sufficient amount induces infertility. Inhibin is also useful in 4 tests to diagnose infertility. Activin has been shown in the literature to be capable of stimulating FSH release from pituitary o cells and accordingly is useful as a fertility inducing therapeutic.
The method of this invention also facilitates the convenient preparation of inhibin, activin and prodomain variants having primary amino acid sequences and/or glycosylation differing :F from the n tive analogues, in particular fusions of immunogenic peptides with inhibin, activin or prodomain sequences.
Brief Description of the Drawings Fig. 1A is a schematic representation of the porcine achain mRNA. Overlapping cDNA clones used in the sequence determination are shown above the diagram of the mRNA structure.
Black boxes on the 3′ ends of A clones indicate that these clones were obtained by specific priming. Untranslated sequences are represented by a line, coding sequences are boxed. The unfilled portion represents the coding region for the signal peptide and pro-sequences, and the cross-hatched area indicates the 134 amino acid a-chain. The scale is in nucleotides from the 5’ end of the LC8x172.mdh longest cDNA clone.
r t 15 4 I 4 i t Fig. 1B shows the nucleotide and predicted amino acid sequence of the porcine inhibin a-chain precursor. Nucleotides are numbered at ‘the left and amino acids are numbered throughout.
The amino acid sequence underlined was used t design a long synthetic DNA probe. The 364 amino acid precursor includes a hydrophobic signal sequence, a pro-region, and the mature a-chain (amino acids 231-364). The proteolytic processing site Arg-Arg (black bar) immediately precedes the NH2-terminus of the mature alpha chain. Several other putative dibasic processing sites present in the pro-region are indicated by open bars. The single potential N-linked giycosylation site is shown by the crosshatched bar. The AATAAA box close to the 3′ end of the mRNA is underlined.
Fig. 2A is a schematic representation of the porcine #A and PB subunit mRNAs with coding sequences boxed. The PA and PB subunits (dashed) are encoded towards the 3′ end of the coding sequences. The 3′ and 5′ untranslated regions are shown as a line. The length of the 5′ and 3′ untranslated region of the PB subunit nRNA is inferred from the size of the mRNA (Fig. 3) and its obvious similarity to the PA nmRNA. Tentative regions of the cDNAs are shown as dashes in the diagram. The relative positions of the overlapping oligo-dT primed cDNA clones and the randomly primed clones (APINPA5s, APINPBls, and APINPB 2 s) are indicated.
The scale is in nucleotides from the 5′ end of the 4.5 kb mRNA.
Fig. 2B is the nucleotide sequence and deduced amino acid sequence of the porcine inhibin P-subunit precursors. The PB sequence is aligned with the PA sequence for maximum homology.
The NH 2 -termini of the P-subunit precursors are indicated by bracket and arrows. Cysteine residues are shaded, possible processing sites are indicated by open bars, and a potential glycosylation site is shown by the cross-hatched box. A very GC- LC8xl72.mdh __il Y~I I I I -7rich region present 3’ to the termination codon intron sequences is underlined and overlined in both sequences. Amino acid sequences used to design oligonucleotide probes are underlined, as is the AATAAA polyadenylation signal. There was one nucleotide difference between APIN-PAB and other clones covering this area.
A G-to-A change causes a change of amino acid 278 from a glycine to a serine. The proteolytic processing site Arg Arg Arg Arg Arg (black bar) immediately precedes the NH 2 terminus of the mature PA subunit, with the prosequences located upstream. The amino acids for the PA subunit only are numbered.
Fig. 3 is a Northern blot analysis ‘of porcine ovarian mRNA with a, PA and PB subunit cDNA hybridization probes. Lanes a, b, c, d, and f are polyA nRNA and e and g are total RNA. The position of the 28S and 18S ribosomal RNAs are shown. Lanes a, d, and e were hybridized with an a-subunit cDNA probe; lanes F and g with a PA subunit specific probe, and lane c with a PB subunit specific probe. The a-subunit LRNA is approximately 1.5 kb, the PA subunit mRNAs are approximately 4.5 kb. The hybridizations shown in lanes a, b, and c were performed with probes of S approximately equal length and specific activity in order to judge relative mRNA levels.
Fig. 4A is a comparison of the human p-TGF amino acid sequence and porcine inhibin PA and fB amino acid sequences. The sequences were aligned around the cysteine residues. Identical residues are boxed, while conservative changes are designated by an asterisk.
Fig. 4B compares the a-subunit sequence with the PAinhibin sequence.
Fig. 5 depicts the construction of a representative L7 recombinant expression plasmid for porcine inhibin.
LC8x172.mdh I-~I w-rWrULunsC-~.~~~ -8- Fig. 6 shows the nucleotide sequence and deduced amino acid sequence of the human a-inhibin cDNA. The 335 amino acid proor inhibin sequence is numbered from the hypothesized signal i cleavage site. 9 Sixteen amino acids of the signal sequence are 19 numbered -1 trough -16. Homology with the porcine sequence I predicts a further 12 amino acid residues in the signal sequence.
1 In this and other figures, putative dibasic processing sites are shown by the open bars, glycosylation sites indicated by crosshatched bars, and amino terminal mature chain processing sites are depicted as black bars. The poly(A) additional signal sequence is underlined. Cysteine residues are shaded.
Fig. 7 is a comparison of the human and porcine ainhibin protein sequences. Spaces are introduced to maximize the S’ homology; positions of non-identity are indicated by stars.
Numbering is as for the porcine sequence, which is one amino acid shorter than the human.
S,,
Fig. 8 shows that the nucleotide and deduced amino acid sequence of the human PA inhibin signal sequence (residues -28 1 through is 28 amino acids with the precursor being 378 amino Sacids in length. The basic processing site is indicated by a black bar, and a potential glycosylation site in the precursor is 25 indicated by a cross-hatched bar above the sequence. Cysteine residues are shaded.
Fig. 9 illustrates the nucleotide and deduced amino acid sequence of human PB inhibin cDNA. The sequence commences at a cysteine residue (position which lines up with the cysteine present at residue 7 in the PA sequence (see Fig. The processing site for the mature PB inhibin is shown as a black bar and a potential glycosylation site as a cross-hatched bar.
Cysteine residues are shaded.
LC8x172.mdh DETAILED DESCRIPTION 44 4 1 4 t4 t 4 4 0 The polypeptides of this invention are the a and chains of inhibin, as well as their multimer forms (activin and inhibin), their prepro forlbs and their prodomains, together with glycosylation and/or amino acid sequence variants of each chain or form thereof. Inhibin (including alleles) from human or animal sources inhibits the basal release of FSH but not of LH from anterior pituitary cells while activin does the opposite (hereinafter referred to as “hormonally active” activin or inhibin).
Generally, amino acid sequence variants will be substantially homologous with the relevant portion of the porcine or human a or P chain sequences set forth in Figs. IB, 2B, 6, 8 and 9. Substantially homologous means that greater than about of the primary amino acid sequence of the candidate polypeptide corresponds to the sequence of the porcine or human chain when aligned in order to maximize the number of amino acid residue matches between the two proteins. Alignment to maximize matches of residues includes shifting the amino and/or carboxyl terminus, introducing .gaps as required and/or deleting residues present as inserts in the candidate. For example, see Figs. 2B and 7 where the PA and PB subunits or human and porcine a-inhibin sequences are aligned for maximum homology. Typically, amino acid sequence variants will be greater than about 90% homologous with the corresponding native sequences shown in Figs. 1B, 2B, 6, 8 and 9.
Variants that are not hormonally-active fall within the scope of this invention, and include polypeptides that may or may not be substantially homologous with either a mature inhibin chain or prodomain sequence, but which are 1) immunologically crossreactive with antibodies raised against the native counterpart or 2) capable of competing with such native counterpart polypeptides for cell surface receptor binding. Hormonally inactive variants I I LC8x172.mdh
I
if
I$
i It0 0 i t i s 21 U110
I
if 1ff *E I f i 4 ii 25
LI
if¥ 1 1 are produced by the recombinant or organic synthetic preparation of fragments, in particular the isolated a or P chains of inhibin, or by introducing amino acid sequence variations so that the molecules no longer demonstrate hormonal activity as defined above, i X Immunological or receptor cross-reactivity means that the candidate polypeptide is capable of competitively inhibiting the binding of the hormonally-active analogue to polyclonal antisera raised against the hormonally-active analogue. Such antisera are prepared in conventional fashion by injecting goats or rabbits S.C. with the hormonally-active analogue or derivative in complete Freunds adjuvant, followed by booster intraperitoneal or S.C. injections in incomplete Freunds.
Variants that are not hormonally active but which are capable of cross-reacting with antisera to hormonally-active inhibin, activin, or prodomains are useful as reagents in diagnostic assays for the native analogues or their antibodies, when insolubilized in accord with known methods, as an agent for purifying anti-native analogue antibodies from antisera, and as an immunogen for raising antibodies to hormonally-active analogues.
This invention includes the pro and/or prepro sequences of the inhibin a or P chain precursors, or their immunologically or biologically active fragments, substantially free of the corresponding mature inhibin chains. These sequences for porcine and human inhibin are shown in Figs. 1B, 2B, 6, 8 and 9. The prepro sequence for the porcine a subunit precursor is the polypeptide comprised by residues 1 to about 230, while the PA subunit pro sequence is comprised by residues 1 to about 308.
These sequences shall be referred to herein as encompassing prodomain sequences.
LC8x172.mdh
J
7j if ij if I~s
I)
Ii
I
I
ii
‘I
I
4 1 .121-
QQ*
444444
O
4g 4 4 o 444 4 rf 4 4, 44’ 44| I I (*1 “f f The a and P subunit prodomain sequences are comprised of several domains bounded by proteolysis sites, any one of which is synthesized herein separately or in combination with other domains, The principal porcine PA domains fall within residues 1 to about 70 (domain about 70 to about 110 (domain II), about 110 to about 180 (domain III), about 180 to about 260 (domain IV), and about 270 to about 309 (domain In particular, the porcine PA domains are GHSAAPDCPSCALATLPKDVPNSQPEVEAV, HILNMLHLKKRPDVTQPVPKAALLNAI, LHVGKVGENGYVELEDDIG, AEMNELMEQTSE I TFAEAGRARKTLRFEISKEGS DLSVVERAEIWLFKVPKANRTRTKV SIRLFQQQ, PQGSADAGEEAEDVGFPEEKSEVLISEKVVDA, STWHIFPVSSSIQRLLDQGKSALDIRTACEQCHETGASLVLLG, and
GHSAAPDCPSCALATLPKDVPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAI,
The porcine BP domains comprise RAAHILLHAVRVSGWLNL as well as homologous P domains having the same sequences. The porcine a domains comprise GPELDRELVLAKVRALFLDALGPPAVTGEGGDPGV and
GSEPEEEDVSQAILFPATGARCGAEPAAGELAREAEEGLFTYVGRPSQHTHSRQVTSAQLWFHTG.,
DRQGMAAAN S S GPLLDLLAS SRG PVAVPMS LGQAPPRWAVLHLAASALPLLTHPVLVLLLRCPLC SCSARPEATPFLVAHTRARPPSGGERA. A typical combination domain polypeptide would be PA domain II linked at its C-terminus to the
NH
2 -terminus of PA domain III. In addition, these domains are fused together by the proteolysis sites found in the sequences shown in Figs. 1B or 2B, by 1 to 4 residue polypeptides that are resistant to hydrolysis (for example, glutaminyl or histidyl residues), or are directly fused, whereby, in all three instances, combination domain polypeptides are produced.
Principal human a chain prodomains are approximately residues 30-199 and 1 to 29, human PA prodomains are approximately residues 1-30, 32-40, 43-59, 62-80, 83-185 and 186-230 while human PB prodomains are approximately residues 1-13, 15-30, 32-59, 62- 145, 148-195 and 198-241 (referring to the numbering system adopted in Figs. 6, 8 and 9, respectively). Combination prodomain polypeptides are within the scope hereof, for example, the PA prodomain at about 43-80, and the PB prodomains at about 1-30 and 444a 4444 44444 4 4 44 4 44 4 44 LC8x172. mdh -12about 32-145. The preferred human a, PA and PB chain prodomains are about residues 1-29, about 43-80 and about 1-30, respectively.
The intact isolated prepro or prodomain PA, PB or a sequences ate best synthesized in recombinant cell culture. The individual subcomponent domains are synthesized by routine methods of organic chemistry or by recombinant cell culture. They then are labelled with a radioisotope or other detectable group such as San erzyme or fluorophore in accord with known methods and used in standard competitive immunoassays to detect the levels of prepro or pro forms of inhibin, including individual domains, in transformants with DNA encoding such forms or their precursors.
This assay is useful in determining whether proteolytic hydrolysis of proinhibin is occurring in the host transformants or their culture media. The assay also is useful in determining whether a rate limiting step in recombinant synthesis is translation of mRNA into the prepro forms or processing of the prepro forms into mature inhibin. For example, high levels of prepro or pro inhibin in cell lysates, but relatively low levels of secreted mature inhibin, woud suggest that the host cell is adequately S transcribing and translating the inhibin DNA, but is not processing the precursorc at an adequate rate. Thus, in this case one would select an alternate host cell.rather than concentrating on improving the transcription or translation efficiency of the transforming plasmid, by selecting an alternate promoter.
The prodomain sequences also are believed to be involved in coordinate modulation of animal physiology in reproductive cycles and fertility.
Amino acid sequence variants are any one of 1) hormonally-active, 2) cross reative with antibodies raised against mature inhibin or prodomain a or P chain sequences, or 3) cross-reactive with inhibin/activin cell surface receptors, but are characterized by a primary amino acid sequence that departs from the sequence of natural inhibins or prodomain sequences.
I-CBx172.mdh
I
-13- 44 *a 4 44 1 ‘444.
These derivatives ordiTiarily are preprepared by introducing insertions, deletions or substitutions of nucleotides into the DNA encoding the target DNA to be modified in order to encode the variant, and thereafter expressing the DNA in recombinant cell culture. Polypeptides having up to about 100-150 residues also are conveniently prepared by in itro synthesis. Such variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation. The variants may exhibit the same qualitative biological activity as the naturally-occurring analogue or may act antagonistically towards such analogues.
While the site for introducing a sequence variation is predetermined, it is unnecessary that the mutation per se be predetermined. For example, in order to optimize the performance of mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed inhibin mutants screened for the optimal combination of desired activity.
Techniques for making substitution mutations at predetermined sites in DNA having a known sequence is well known, for example M13 primer mutagenesis.
Mutagenesis is conducted .by making amino acid insertions, usually on the order of about from 1 to 10 amino acid residues, or deletions of about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any subcombination may be combined to arrive at a final construct. Insertions include amino or carboxyl-terminal fusions, e.g. a hydrophobic extension added to the carboxyl terminus. Preferably, however, only substitution mutagenesis is conducted. Obviously, the mutations in the encoding DNA must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.
*4 @44 -4- LC8x172.mdh -14- Not all mutations in the DNA which encode the polypeptides herein will be expressed in the final secreted product. For example, a major class of DNA substitution mutations Sare those in whioh ei different secretory leader or signal has been substituted for the native porcine or human a or P chain secretory leader, either by deletions within the leader sequence or by substitutions, wherein most or all of the native leader is exchanged for a leader more likely to be recognized by the intended host. For example, in constructing a procaryotic expression vector the porcine or human a or 8 chain secretory leader is deleted in favor of the bacterial alkaline phosphatase or heat stable enterotoxin II leaders, and for yeast the leader is substituted in favor of the yeast invertase, alpha factor or acid phosphatase leaders. However, the porcine and human secretory leaders are recognized by many heterologous higher eukaryotic cells. When the secretory leader is “recognized” by the host, the host signal peptidase is capable of cleaving a fusion of the leader polypeptide fused at its C-terminus to the mature inhibin or prodomain such that mature inhibin or prodomain polypeptide is secreted.
Another major class of DNA mutants that are not expressed in final form as amino acid sequence variations are nucleotide substitutions made in the DN\ to enhance expression, primarily to avoid 5′ stem and loop structures in the transcribed ERNA (see de Boer Lt al., EP 75,444A) or to provide codons that are more readily transcribed by the selected host, e.g. the well-.
known preference codons for E, S&l or yeast expression. These substitutions may or may not encode substituted amino acid residues, but preferably do not.
Insertional and deletional amino acid sequence variants are proteins in which one or more amino acid residues are introduced into or removed from a predetermined site in the target LC8x172.mdh
I
inhibin, activin, prodomain or proform of inhibin or activin.
Most commonly, insertional variants are fusions of heterologous proteins or polypeptides to the amino or carboxyl terminus of the a or P chains, the prodomaiin or other inhibin derivatives.
Immunogenic derivatives are made by fusing an immunogenic polypeptide to the target sequence, e.g. a prodomain polypeptide, by synthesis in vitro or by recombinant cell culture transformed with DNA encoding the fusion. Such immunogenic polypeptides preferably are bacterial polypeptides such as trpLE, betagalactosidase and the like, together with their immunogenic fragments. Other insertions entail inserting heterologous eukaryotic the herpes virus gD signal) or microbial secretion signal or protease processing sequences upstream from the NH 2 -terminus of the protein to be secreted. Deletions of cysteine or other labile residues also may be desirable, for example in increasing the oxidative stability of the a or P chain.
Deletional derivatives will produce a or P chain fragments. Such fragments, when biologically or immunologically active, are within the scope herein. For instance, a fragment comprising PB or PA residues about from 11 to 45 (numbered from mature Gly) is to be included within the scope herein.
Immunogenic conjugates of prodomain polypeptides, inhibin and activin are readily synthesized in recombinant cell culture as fusions with immunogenic polypeptides, e.g. betalactamase or viral antigens such as the herpes gD protein, or by preparation of the polypeptides in unfused form (by recombinant or in vitro synthetic methods) followed by covalent cross-linking to an immunogenic polypeptide such as keyhole limpet hemocyanin or STI using a divalent cross-linking agent. The immunogenic polypeptides are formulated with a vaccine adjuvant, e.g. alum or Freunds. Methods for preparing proteins in adjuvants and for cross-linking are well-known per se and would be employed by one skilled in the art, as are methods for vaccinating animals. The immunogenic conjugates are useful in preparing antibodies to the LCBx172.mdh -16- 15 I t r t t I 20 prodomain region for use’ in monitoring inhibin manufacture or for ij vivo vaccination with the objective of raising antibodies capable of modulating animal physiology in reproductive cycles and fertility. Typically, the prodomain or its immunogen is administered in varied doses to fertile laboratory animals or swine and the reproductive cycles and fertility of the animals monitored, together with assays of serum levels of anti-immunogen or prodomain by routine competitive or sandwich immunoassay.
Substitution derivatives are produced by mutating the DNA in a target codon, so that thereafter a different amino acid is encoded by the codon, with no concomitant change in the number of residues present in the molecule expressed from the mutated DNA. Substitutions or deletions are useful for example in increasing the stability of the proteins herein by eliminating proteolysis sites, wherein residues are substituted within or adjacent to the sites or are deleted from the sites, or by introducing additional disulfide bonds through the substitution of cysteine for other residues. Substitutions are useful for facilitating the synthesis or recovery of mature or prodomain a or S chains. For example, methionine residues within the mature inhibin sequences are substituted or deleted, prepro sequences deleted,- methionine inserted at the 1 site immediately NH 2 terminal to the mature NH 2 terminal residue and another sequence inserted N-terminal to the exogenous methionine. The inhibin derivative in this case is expressed as a fusion having an intermediate methionyl residue, which in turn is cleaved at this residue by cyanogen bromide in accordance with known practice.
The mature inhibin derivative released from the fusion is recovered.
Exemplary porcine inhibin derivatives are [Asn 266 >Gln]Inha (to remove the putative glycosylation site), [Cys 325 or Cys 324 ->A]Inha, [Cys 361 or Cys 363 ->A]Inha, [Lys 321 or Lys 322 A]InhPA or (Lys 322 ->His or Ser]InhpA (to inactivate a potential LC8x172.mdh -17a94 2 0 9 t proteolysis site), [LYs 315 ->Arg; Val 31 6 ->Thrl InhPiA (to create a PA/PB hybrid), 1CYs 3 8 8 or Cys 3 9 0->A]IflhPA [Lys 4 lv.>Gln]InhpA, [Arg 3 l 5 ->Lys, Val 3 l 6 ->Thr]InhpB (to create a PB/PA hybrid), [Cys 3 lg or Cys 32 O->A&]IflhPB [Pro 3 B1 Gly 3 82-> Pro Phe Gly]InhPB, and [Arg 3 g 5 ->GllhIn1hPB, wherein’Inh is an abbreviation for inhibin and the residue numbers for InhfiB are those used for the corresponding InhPiA residue (see Fig. 2B).
The hPA amino acid positions which are principal candidates for mutational substitution or deletion (or adjacent to which residues may be inserted) include residues 293-297, 364-376 and 387-398 (Fig. Preferably, the proline, cysteine and glycine residues within these sequences are not modified.
Candidates having greater potency than inhibin or activin, or which serve as inhibin or activin antagonists, are identified by a screening assay wherein the candidate is diluted into solutions contaiigcntt amounts of inhibin or ‘kctivin andth compositions assayed in the rat pituitary cell assay. Candidates which neither antagonize or agonize inhibin or activin are screened for utility in immunoassays for inhibin or activin by measuring competitive immunodisplacement of labelled inhibiri or activin of the native hormones fzo~i polyclonal antibody directed against the native hormones. Exemplary contemplated sequence variants of hfiA include Phe 3 0 2 ->Ile or Leu; G1n 2 9 7 ->AsP or Lys; TrP 3 0 7 ->Tyr or Phe; Trp 3 1 0 ->Tyr or Phe; 11e 3 ll->Phe or Val; Tyr 3 1 7 ->Trp or Thr; His 3 l 8 ->Lys; Ala 3 l9->Ser; Asn 3 2 0-)Oln, Tyr or His; Tyr 321 ->Thr or Asp, Phe 340 ->Tyr (a TGF-P/PA intrachain hybrid); 11is 3 5 3 ->Asp; His 3 5 3 ->Lys (a PA/PB hybrid); Phe 3 5 6 ->Tyr; Val 3 6 4 ->Phe; Val 3 6 4 ->Leu; Tyr 3 7 5 ->Thr; Tyr 3 7 6 ->Trp; Asn 3 8 9 ->-Gin.
His or Lys; 11e 3 g 1 ->Leu or Thr; Met 39 O ->Leu or Ser; Val 392 ->Phe, Glu, Thr or le. Comparable modifications are made in the human PB chain. For example, hPA contains a phenylalanyl residue at position 302, and hPB also contains a phenylalanyl residue at a homologous position (264, Fig. 9) when aligned in the samne fashion as is shown for porcine PB in Fig. 4A. Thus, since the Phe 3 0 2 LC8xl72 .ndh -18residue of #A is described above as substituted by isoleucinyl or leucinyl, the Phe 264 of PB is substituted with the same residues.
A factor in establishing the identity of a polypeptide Sas inhibin, activin or an inhibin variant is the ability of antisera which are capable of substantially neutralizing the hormonal activity of mature inhibin or activin to also substantially neutralize the hormonal activity of the polypeptide Sin question. However it will be recognized that immunological Sidentity and hormonal activity are not necessarily coextensive.
For example, a neutralizing. antibody for inhibin may not bind a candidate protein because the neutralizing antibody happens to not be directed to specifically bind a site on inhibin that is critical to its activity. Instead, the antibody may bind an innocuous region and exert its neutralizing effect by steric hinderance. Therefore a candidate protein mutated in this innocuous region might no longer bind the neutralizing antibody, I I I i but it would nonetheless be inhibin in terms of substantial ,homology and biological activity.
It is important to observe that characteristics such as molecular weight, isoelectric point and the like for a native or wild type mature inhibin or activin obtained from follicular fluid or other tissue sources are descriptive only for the native form.
Variants contemplated by the foregoing definition will include other polypeptides which will not exhibit all of the characteristics of native analogue. For example, inhibin derivatives like the insertion mutants, deletion mutants, or fusion proteins described above will bring inhibin outside of the molecular weight established for the corresponding native inhibin because fusion proteins with mature inhibin or proinhibin itself as well as insertion mutants will have a greater molecular weight than native, mature inhibin. On the other hand deletion mutants of native, mature inhibin will have a lower molecular weight.
Finally, post-translational processing of preproinhibin chains in LC8x172.mdh 1 Lir~
I:I
Irir 111 iit 1) i’ -19- 10 Io
I
4 heterologous cell lines may not be accomplished with the fidelity exercised by the homologous host cell, thereby resulting in some variation in the amino termini of the a and/or P chains. This variation may be encountered as residual prosequence remaining with the mature protein, or the loss of several mature residues that are cleaved off with the prosequence. The same is true with processing of the preprotein in heterologous recombinant cells.
Covalent modifications of inhibin, activin or prodomains are included within the scope hereof and include covalent or aggregative conjugates with other chemical moieties. Covalent derivatives are prepared by linkage of functionalities to groups which are found in the inhibin amino acid side chains or at the Nor C-termini, by means known in the art. For example, these derivatives will include: aliphatic esters or amides of the carboxyl terminus or residues containing carboxyl side chains, aspartyl residues; O-acyl derivatives of hydroxyl groupcontaining residues such as seryl or alanyl; and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g. lysine or arginine. The acyl group is selected from the group of alkyl-moieties (including C3 to CO1 normal alkyl), thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups preferably are difunctional compounds known per se for use in cross-linking proteins to insoluble matrices through reactive side groups, e.g. m-Maleimidobenzoyl-N-hydroxy succinimide ester. Preferred derivatization sites are at histidine residues.
Covalent or aggregative derivatives of mature inhibin, activin or prodomain sequences are useful as reagents in immunoassay or for affinity purification procedures. For example, inhibin or prodomain is insolubilized by covalent bonding to cyanogen bromide-activated Sepharose by methods known per se or adsorbed to polyolefin surfaces (with or without glutaraldehyde r LC8x172.mdh Il
IT
P1 if Si
U
Ii
U
Li Ii If (1
I
4 4
I
I
14 1′ 4 4r Ifr 4 *r Cfr 20 cross-linking) for use in the assay or purification of antiinhibin or anti-prodomain antibodies or cell surface receptors.
Inhibin or a prodomain sequence also is labelled with a detectable group, radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates or conjugated to another fluorescent moiety for use in diagnostic assays, especially for diagnosis of inhibin or prodomain levels in biological samples by competitive-type immunoassays.
DNA which encodes the complete a and P chains of inhibin/activin is obtained by chemical synthesis, by screening reverse transcripts of mRNA from ovary, or by screening genomic libraries from any cell. It may be more efficient to simply synthesize portions of the DNA desired since screening is required to identify DNA in cDNA or genomic libraries that encode the a and P chains. Synthesis also is advantageous because unique restriction sites can be introduced at the time of preparing the DNA, thereby facilitating the use of the gene in vectors containing restriction sites otherwise not present in the native sequence, and steps can be taken to enhance translational efficiency as discussed above, without the need to further modify the DNA as by mutagenesis or the like. cDNA encoding the a or j chains is free of untranslated intervening sequences (introns) as well as free of flanking DNA encoding other proteins homologous to their source.
DNA encoding the a and 8 chains is obtained from other sources than porcine or human by obtaining a cDNA library from the ovary of the target animal, conducting Southern analysis with labelled DNA encoding porcine or human a and P chains or fragments thereof (generally, greater than 100 bp) in order to detect clones in the cDNA library that contain homologous sequences, analyzing the clones by restriction enzyme analysis and nucleic acid sequencing so as to identify full-length clones and, if full length clones are not present in the library, LC8x172.mdh -21recovering appropriate fragments from the various clones and ligating them at restriction sites common to the clones to assemble a ‘clone encoding the full-length molecule. As shown infra, any sequences missing’from the library can be obtained by Sthe 3′ extension on ovarian mRNA of synthetic oligodeoxynucleotides complementacy to cDNA identified by screening the library, or homologous sequences are supplied from known animal cDNAs. This is particularly useful in constructing pre or prepro inhibin sequences to facilitate processing of preproinhibin to mature inhibin from the desired species.
Porcine and human ovarian cDNA libraries initially were probed for DNA encoding inhibin sequences using labelled oligonucleotides whose sequence was based on the partial amino acid sequence determined from analysis of purified porcine inhibin or, in the case of human cDNA, porcine cDNA probes. However, once having described cDNA encoding human and porcine inhibin and prodomains, one skilled in the art would realize that precisely hybridizing probes can be prepared from the described sequences in order to readily obtain the remainder of the desired human or porcine gene.
Nucleotide sequence analyses .of identified porcine and human cDNA clones revealed the structures of the biosynthetic precursors of both forms of inhibin. Interestingly, the two inhibin chains are not derived from a single processed precursor.
Instead, the two chains are translated from separate mRNAs and then assembled into the disulfide crosslinked two-chain molecule.
Figs. 1B and 2B and 6, 8 and 9 depict the DNA encoding the polypeptide chains constituting porcine and human preproinhibin and preproactivin. Obviously, degenerate codons may be substituted for those disclosed in these figures where the same amino acid is encoded. The DNA of Figs. 1B, 2B, 6, 8 and 9 is mutated in order to encode the amino acid variants of the a and LC8x172.mdh -22chains described above. In particular, the prepro sequences are deleted and a start codon inserted immediately 5′ to the mature chain in question so that the chain is expressed directly in recombinant culture. The DNA also is labelled, e.g. with Sradioactive phosphorous, ana used to screen ovarian cDNA libraries from other species to identify a or 8 chain encoding DNA from such other species as is generally described above.
Covalent labelling of this DNA is accomplished with a detectable substance such as a fluorescent -group, a radioactive atom or a chemiluminescent .group by methods known pe se. The labelled DNA is then used in conventional hybridization assays.
Such assays are employed in identifying vectors and transformants as described in the examples infra, or for in vitro diagnosis such 15 Sas detection of mRNA in tissues.
Lengthy sequences desirably are synthesized in host cells transformed with vectors containing DNA encoding them, e.g.
inhibin or prodomain sequence. Vectors are used to amplify the DNA which encodes the chains, either in order to prepare quantities of DNA for further processing (cloning vectors) or for expression’ of the chains (expression vectors). An expression vector is a replicable DNA construct. in which a DNA sequence encoding an a or P chain is operably linked to suitable control sequences capable of effecting their expression in a suitable host. Cloning vectors need not contain expression control sequences. Such control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites (for prokaryotic expression), and sequences which control termination of transcription and translation. The vector should include a selection gene to facilitate the stable expression of the desired polypeptide and/or to identify transformants. However, the selection gene for maintaining a and/or P chain expression can be supplied by a separate vector in cotransformation systems using LC8x172 .dh -23eukaryotic host cells.
Vectors comprise plasmids, viruses (including phage), and integratable DNA fragments fragments that are integratable into the hos’genome by recombination. The vectors described herein for use in eukaryotic cell expression of inhibin a and/or p chains contain plasmid sequences for cloning in microbes, where the plasmid replicates autonomously from the host genome, but the DNA is believed to integrate into the eukaryotic host cell genome upon transformation. Similarly, bacillus vectors that genomically integrate by homologous recombination in bacillus also are useful. However, all other forms of vectors which serve an equivalent function and which are, or become, known in the art are suitable for use herein.
Suitable vectors generally will contain replicon t (origins of replication, for use in non-integrative vectors) and control sequences which are derived from species compatible with the intended expression host. Transformed host cells are cells which have been transformed or transfected with vectors containing inhibin a and/or P chain encoding DNA. Transformed host cells contain cloned DNA and, when transformed wxth an expression vector, also express the a and/or p. chains. The expressed polypeptides will be deposited intracellularly or secreted into either the periplasmic space or the culture supernatant, depending upon the host cell selected and the presence of suitable processing signals in the expressed protein, e.g. homologous or heterologous signal sequences.
DNA regions are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein which participates in the secretion of the polypeptide; a promoter is operably linked 3 5 to a coding sequence if it controls the transcription of the LC8x172.mdh -24sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation, Generally, operably linked means that the DNA sequences being linked are contiguous and, in the case of secretory leaders, j contiguous and in reading phase.
Suitable host cells are prokaryotes, yeast or higher eukaryotic cells. Prokaryotes include gram negative or gram positive organisms, for example E. 2co or Bacilli. Higher eukaryotic cells include established cell lines of mammalian origin as described below. A preferred host cell is EL r’Li 294 (ATCC 31,446) although other prokaryotes such as J. coli B, E.
col X1776 (ATCC 31,537), E. coli W3110 (ATCC 27,325), pseudomonas species, or Serratia Marcesans are suitable.
Expression vectors for host cells ordinarily include an origin of replication (where extrachromosomal amplification is desired, as in cloning, the origin will be a bacterial origin), a promoter located upstream from the inhibin coding sequences, together with a ribosome binding site (the ribosome binding or Shine-Dalgarno sequence is only needed for prokaryotic expression), RNA splice site (if the inhibin DNA contains genomic DNA containing one or more introns), a pplyadenylation site, and a transcriptional termination sequence. As noted, the skilled artisan wv 1 l appreciate that certain of these sequences are not required for expression in certain hosts. An expression vector for use with microbes need only contain an origin of replication recognized by the intended host, a promoter which will function in the host and a phenotypic selection gene, for example a gene encoding proteins conferring antibiotic resistance or supplying an auxotrophic requirement. Inhibin DNA is typically cloned in E.
toli using pBR322, a plasmid derived from an 1. col2 species (Bolivar, e1 al., 1977, “Gene” 2: 95). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells.
LC8x172.mdh Expression vectors, unlike cloning vectors, must contain a promoter which is recognized by the host organism. This is If generally a promoter homologous to the intended host. Promoters S most commonly used in recombinant DNA constructions include the Rlactamase (penicillinase) and lactose promoter systems (Chang It al., 1978, “Nature”, 275: 615; and Goeddel Ai., 1979, “Nature” 28M: 544), a tryptophan (trp) promoter system (Goeddel e al., 1980, “Nucleic Acids Res.” 4057 and EPO Appl. Publ. No. 36,776) and the tac promoter De Boer e ali., 1983, “Proc. Nat’l. Acad.
Sci. 80: 21-25]. While these are the most commonly used, other known microbial promoters are suitable. Details concerning their nucleotlde sequences have been published, enabling a skilled worker operably to ligate them to DNA encoding inhibin in plasmid vectors (Siebenlist e al., 1980, “Cell” 2,Q: 269) and the DNA I ,,iencoding inhibin or its derivative. Promoters for use in prokaryotic expression systems also will contain a Shine-Dalgarno sequence operably linked to the DNA encoding the inhibin, the S.D. sequence is positioned so as to facilitate 0 translation. Generally, this means that the promoter and S.D.
sequences located upstream from the second codon of a bacterial structural gene are substituted for the sequences of prepro inhibin located 5′ to the mature a and/or P chains.
25 In addition to prokaryotes, eukaryotic microbes such as yeast cultures are transformed with inhibin-encoding vectors.
Saccharomvces erevilslae, or common baker’s yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other strains are commonly available and useful herein. Yeast vectors generally will contain an origin of replication from the 2 micron yeast plasmid or an autonomously replicating sequence (ARS), a promoter, DNA encoding the a and/or Schain, sequences for polyadenylation and transcription termination, and a selection gene. A suitable plasmid for expression in yeast is YRp7, (Stinchcomb e al., 1979, “Nature”, LC8xl72.mdh .26- A9; Kingsman It 1979, “Gene”, 2: 141; Tschemper etA_.
1980, “Gene”, This plasmid already contains the “r 1 genie which provides a selection marker for a mutant strain of yeast lacking the ability to’grow in tryptophan, for example ATOC No. 44076 or P$EP4-1 (Jones, 1977, “Genetics”, j, 12). The presence of the tipl lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.
Suitable promoting sequences in yeast vectors include the promoters for netallothionein, 3-plhoiphoglycerate kinase (Hitzeman &t Al1., 1980, Biol. Chem.”, M: 2073) or Pther 4glycolytic enzymes (Hess &t Al., 1968, Adv. Enzyme Reg.”, 2: 149; and Holland Aln., 1978, “Biochemistry”. 12: 4900), such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose- 6-phosphate isomerase, 3-popolcrt uae pyruvate kinase, triosephosphate isome’rase, phosphoglucose isomerase, and glucokinase. Suitable vectors and promoters for use in yeast expression ar furi2-‘er described 4n R. Hitzeman et. pl., EP 73,657A.
Other yeast promoters, which have the additional advantage of transcription contiolled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the aforementioned metallothionein and glycereldehyde-3- phosphate dehydrogenase, as well as enzymes.
responsible for maltose and galactose utilization. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression vector 31 of the inhibin or derivative coding sequences to provide termination and polyadenylation of the mRNA.
LC8xl72 .udh -27- Cultures of cells derived from multicellular organisms are the preferred host cells herein because it is believed that expression of hormonally active inhibin or activin will only occur in such cells, with microbi&l expression resulting at most only in immunological cross-reactivity. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Propagation of vertebrate cells in culture r se has become a routine procedure in recent years (Tissue L Culture, Academic Press, Kruse and Patterson, editors (1973)].
Suitable host cells for expressing a or 6 chains in higher eukaryotes include: monkey kidney CVI line transformed by (COS-7, ATCC CRL 1651); baby hamster kidney cells (BHK, ATCC CRL 10); chinese hamster ovary-cells-DHFR (described by Urlaub and Chasin, PNAS (USA) 2Z: 4216, [1980]); mouse sertoli cells (TM4, Mather, Biol. Reprod. 21: 243-251 [1980]); monkey kidney cells (CVI ATCC CCL 70); african green monkey kidney cells (VERO- 76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT H 060652, ATCC CCL 51); rat hepatoma cells (HTC, Ml, 54, Baumann, At Al.; J. Cell. Biol. 85.: 1-8 [1980]) and TRI cells (Mather, J.P. ft Al., Annals N.Y. Acad. Sci. j3: 44-S8 [1982]).
The transcriptional and translation control sequences in vertebrate cell expression vectors preferably are provided from viral sources. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and most preferably Simian Virus (SV40). The early and late promoters of SV40 are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers rt al., 1978, “Nature”, 273: 113). Smaller or larger fragments may also be used, provided the approximately 250 bp sequence extending from the Hind III site toward the Bgl I site LC8x172.mdh -28located in the viral origin of replication is included. Further, it is also possible to utilize the genomic promoters, control and/or signal sequences normally associated with the a or 3chains, provided such control sequences are compatible with and recognized by the host cel-.
An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be obtained from SV40 or other viral Polyoma, Adenovirus, VSV, or BFV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
15 Rather than using vectors which contain viral origins of oo,,,O replication, mammalian cells are cotransformed with DNA encoding a So selectable marker and DNA encoding the a and/or P chains. An example of a suitable selectable marker is dihydrofolate reductase (DIFR) or thymidine kinase. Such markers are proteins, generally 2 enzymes that enable the identification of transformant cells, cells which had been competent to take up exogenous DNA.
o Generally, identification is by survival of transformants in o culture medium that is toxic to untransformed cells or from which ‘o the cells cannot obtain a critical nutrient without having taken oOo a 25 up the marker protein.
out, o In selecting a preferred host mammalian cell for transfection by vectors which comprise DNA sequences encoding both S” inhibin and DHFR, it is appropriate to select the host according to the type of DHFR protein employed. If wild type DHFR protein is employed, it is preferable to select a host cell which is deficient in DHFR thus permitting the use of the DHFR coding sequence as a marker for successful transfection in selective medium which lacks hypoxanthine, glycine, and thymidine (hgt”).
An appropriate host cell in this case is the Chinese hamster ovary LC8xl72.mdh -29- (CHO) cell lie deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin, 1980, “Proc. Nat’l.
i Acad. Sci.” (USA) 77: 4216.
On the other hand,-if DNA encoding DHFR protein with low binding affinity for methotrexate (MTX) is used as the controlling I sequence, it is not necessary to use DHFR resistant cells.
Because the mutant DHFR is resistant to MTX, MTX containing media can be used as a means of selection provided that the host cells are themselves MTX sensitive. Most eukaryotic cells which are capable of absorbing MTX appear to be methotrexate sensitive. One such useful cell line is a CHO line, CHO-KI (ATCC No. CCL 61).
Preferably, transformants are first selected for neomycin resistance (the transfection is conducted together with DNA encoding the neomycin resistance gene), followed by MTX amplification of the a and/or P chain expression as the case may be. See Kim et al., “Cell” 42: 129-138 (1985) and EP 160,457A.
Other methods suitable for adaptation to the synthesis of a and/or p chains in recombinant vertebrate cell culture are described in M-J. Gething et al., “Nature” 293: 620-625 (1981); N. Mantel et al., “Nature” 281: 40-46; and A. Levinson et al., EP 117,060A and 117,058A.
The inhibin a chain is expressed in recombinant cell culture with or without either of the p-chain molecules.
Similarly, host cells are transformed with DNA encoding either or both of the mature p-chains. Based on analogy to TGF-p, the mature p-chains are capable of forming homodimers or PA/PB heterodimers upon expression in recombinant culture. These structures are not inhibin and will be referred to herein as fchain dimers or activin. These are useful in the preparation of active inhibin, serving as sources of the f-chain, or are used as gel electrophoresis standards to detect the diversion into p-chain dimers of p-chains synthesized in a and P chain cotransformants.
LC8xl72.mdh
I
1 cgj As will be seen in Example 4, this is not a hypothetical problem.
Of course, the dimers also are useful in modulating reproduction as noted above.
B-chai hetero or homodimers are separated by j, vitro unfolding of the individual chains followed by oxidative disulfide bond formation with the a-chain in accord with processes generally i known pe se. Preferably, however, in preparing mature inhibin the recombinant host is transformed with DNA encoding both the a and either of the P-chains. The intact hormonally active molecule is then assembled by the host cell in vivo, and it is thus unnecessary to combine the two chains by in vitro processing. The DNA encoding the a and P-chains is preferably located on the same vector, and under the control of the same promoter, but this is 15 15 not essential.
Certain a-chain amino acid sequence variants identified in the screening procedure will not bind to pituitary cell surface receptors nor as a consequence will they exhibit hormonal activity. Such variants, when expressed as homodimers in recombinant cell culture, are useful in immunoassays for activin when they bear immunological epitopes cross-reactive with the native p-chain. In addition, such variants are coexpressed with DNA encoding hormonally active P-chain to yield a hybrid bearing native and variant p-chain. In this case the variant serves to stabilize the structure of the native p-chain. This form of 3chain heterodimer is useful, like the homodimer, in immunoassays for activin. It also may function as an activin antagonist.
The activin/inhibin a-chains also are coexpressed with TGF-p in order to produce p-chain/TGF-P hybrids. Vectors and methods for the expression of TGF-P are known. For example, see Derynck et al., Human Transforming Growth Factor-p Complementary DNA Sequence and Expression in Normal and Transformed Cells Nature” 16: 701-7Ce (1985). Cotransformation of mammalian host LC8x172.ndh ii*~ i~L: 1- i_ -31cells by vectors bearing the TGF-p gene as described by Derynck et pl. together with t;he PA or PB chains of activin/inhibin will result in secretion of a proportion of P-chain/TGF-P hybrid dimers. This hybrid is useful in preparing TGF-P/P-chain immunogens or in immunoassays.
Inhibin, activin or prodomain sequences are recovered from transformed cells in accord with p se known procedures.
When a polypeptide is expressed in recombinant bacteria as a refractile body, the desired polypeptide is recovered and refolded by conventional methods. Alternatively, the culture supernatants from transformed cells that secrete activin or inhibin, preferably mammalian cells, are simply separated from the cells by centrifugation. Then the inhibin generally is purified by successive purification procedures that include heparin-Sepharose affinity chromatography, gel filtration and at least one and preferably several RP-HPLC (reverse phase high pressure liquid chromatography) steps using different conditions in the stationary phase and/or mobile phase. Prodomain sequences produced by in vitro synthesis will be purified by conventional methods.
The prodomain polypeptides that are preferred for use herein are recovered from the culture media of recombinant cells transformed to synthesize the a and/or f chains as appropriate for the desired prodomain. Specifically, they are recovered by separating the culture medium polypeptides on native electrophoresis gel, excising bands having the predicted molecular weight and thereafter purifying the eluted polypeptides further, for example by FPLC or HPLC, followed by amino acid sequence determination for the substantially homogeneous separated polypeptides. Purified prodomain polypeptides then are used to raise antibodies, in rabbits, which when used in immunoaffinity purification will simplify the recovery of the prodomains.
LC8x172.mdh 1J -32- 15 ~I I I r I 11 114 13 S I If S I S 1.1.1 5 11 S C I 1 In the preferred procedure for isolating porcire hormonally active inhibin, clarified transformant culture supernatant or cell lysate is first purified by heparin-Sepharose affinity chromatography, next by gel filtration on Sephacryl S-200 gel and then with four successive RP-HPLCs using different mobile phase gradients and/or derivatized silica supports. Preferably, stationary phases having relatively low hydrophobicity are used, with C3-CB columns being preferred and C3-C5 and phenyl columns bting particularly preferred. Solute specificity of the mobile phase is preferably adjusted by varying the concentration of an organic component, particularly acetonitrile. Although a single RP-HPLC fractionation significantly increases the purity relative to the gel-fAltrated material, two or more, and preferably four, RP-HPLC purifications are generally performed subsequent to successive treatment by heparin-Sepharose chromatography and gel filtration. This method has been found to be adaptable to the purification of human inhibin from recombinant cell culture as well.
The first step of the purification is heparin-Sepharose affinity chromatography, in which the protein is adsorbed to the Sepharose-bound heparin moieties under application conditions, and the adsorbed inhibin material is recovered by IM NaCl elution.
This step greatly expedites the purification procedure for crude extracts because it allows a relatively large volume of a crude extract to be processed fairly rapidly while recovering an amount of protein exhibiting total inhibin activity equal to at least of that of the crude extract.
For the detection of inhibin &ctivity in the various column fractions, aliquots ranging from 0.01% to 0.1% by volume are removed, and after adding 100 pg human serum albumin in 100 pI water, the solvents were evaporated in a Speed-Vac concentrator (Savant, Hicksville, The residue as redissolved in 3 ml 1% fetal bovine serum in HDMEM, filtered through a Millex-GS 0.22 pm LC8x172.mdh -33filter (Millipore Corp., Bedford, MA) and assayed in duplicate.
To speed up the bioassays during the purification process, only basal inhibition of FSH secretion exerted by the inhibin activity is determined and plotted in the region where the inhibin proteins were expected to,migrate itr the chromatograms.
To perform the heparin-Sepharose affinity chromatography, cell debris is spun down in a Beckman J2-21 centrifuge (Beckman Instruments, Inc., Palo Alto, CA.) using a JA- 20 rotor at 10,000 rpm for 30 minutes. One half of the supernatant is diluted to 10 times its volume by the addition of 0.01 M Tris-HCl containing 0.1 M NaC1, pH 7, in an Erlenmeyer flask and pumped simultaneously via silastic tubes (0.76mm ID) into heparin-Sepharose (Pharmacia Fine Chemicals, Piscataway, columns (3.5 x 9 cm) by two Rabbit 4-channel peristaltic 4 pumps (Rainin Instrument Co., Inc., Emeryville, CA) at 40 ml/hr per column. After all the fluid has been pumped through the heparin-Sepharose, the eight columns are washed simultaneously with 0.01 M Tris-HCl, pH 7, containing 0.1 M NaC1 in the same manner. The adsorbed proteins with inhibin activity are removed by washing the eight columns simultaneously with 0.01 M Tris-HCl containing 1 M NaC1, pH 7, as above, and the wash is collected into fractions. The inhibin activity is monitored by the n vitro bioassay described above. The columns are regenerated by further washing with 2M NaC1 in 0.01 M Tris-HCl, pH 7, and re-equilibrated with 0.01 M Tris-HCl containing 0.1 M NaCI for purificatior of remaining extract.
Next, the material is fractionated by gel filtration to separate proteins generally according to their molecular weights.
The fractions having inhibin activity extracted by the heparinw Sepharose columns are pooled and dialyzed overnight to remove NaC1 in a 28.6 mm cylinder diameter Spectrapor No. 3 membrane tubing with M r cutoff at 3,500 (Spectrum Medical Industries, Inc., Los Angeles, CA.) against 30% acetic acid. The retained fluid is LC8x172.mdh 04 -34centrifuged, as above, to remove a white precipitate, and the supernatant is divided into equal portions for applying to 5 x 100 cm Sephacryl S-200 superfine columns (Pharmacia Fine Chemicals, Piscataway, Each column is eluted with 30% acetic acid at 20 ml for 22 min., and the column fractions are monitored by UV absorption at 280 nm and by bioassay.
The bioassay-positive protein from the S-200 columns is pooled and lyophilized. The lyophilized material is dissolved in 0.2N acetic acid (1 ml/ml) and filtered through a Millex-HA 0.45 Sm filter (Millipore Corp., Bedford, The filtrate is applied directly onto a 1 x 25 cm Vydac 5-pm particle-size C4 column (The Separations Group Hesperia, CA.) and developed with a gradient of TEAP buffer. In the TEAP system, buffer A consists of 0.25 N triethylammonium phosphate pH 3, and buffer B is acetonitrile in buffer A. After all the filtrate had been loaded, the column is washed with the aqueous buffer A until the UV absorption reached baseline. The fractions exhibiting inhibin activity are separated in a Beckman 332 gradient liquid chromatography system (Beckman Instruments, Inc., Berkeley, CA.) equipped with a Spectroflow 757 UV detector (Kratos Analytical Instruments,’Ramsey, a Soltec 220 recorder (Soltec Corp., Sun Valley, CA.) and a Redirac 2112 fraction collector (LKB Instruments, Inc., Gathersburg, MD). Zones of inhibin activity are detected by bioassay.
Inhibin protein containing the PB chain is further purified free of inhibin containing the PA species, if desired, bytwo more RP-HPLC steps. The first step uses a 1 x 25 cm Vydac pm-particle-size C4 column and a trifluoroacetic acid (TFA) buffer system and the second step employs a 1 x 25 cm Vydac particle-size Phenyl column and the TEAP buffer system. In the TFA system, buffer A contains 1 ml trifluoroacetic acid in 999 ml water and buffer B is I ml trifluoroacetic acid in 199 ml water and 800 ml acetonitrile. The two inhibin species elute LC8x172 .mdh separately. Inhibin accumulated from a few batches was concentrated by RP-HPLC using a 0.46 x 25 cm Aquapore RF-300 pm-particle-size column (Brownlee Labs., Santa Clara, CA.) and the TFA buffer system. Ordinarily, however, this purification step will not be used4iwlth cell.-ulture supernatants from transformants with DNA encoding only the PA or PB chains.
Inhibin, activin, prodomain sequences or their variants are administered in the form of pharmaceutically acceptable nontoxic salts, such as acid addition salts or metal complexes, with zinc, iron or the like (which are considered as salts for purposes of this application). Illustrative of such acid Saddition salts are hydrochloride, hydrobromide, sulphate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate and the like. Intravenous administration in isotonic saline, phosphate buffer solutions or the like is suitable.
The polypeptide herein should be administered under the guidance of a physician, and pharmaceutical compositions will usually contain an effective amount of the peptide in conjunction with a conventional, pharmaceutically-acceptable carrier. The I dosage will vary depending upon the specific purpose for which the protein is being administered, and dosage levels in the range of about 0.1 to about 1 milligram per Kg. of body weight may be used i when inhibin is administered on a regular basis as a male contraceptive.
Inhibin, activin, prodomain sequences or their variants desirably are administered from an implantable or skin-adhesive sustained-release article. Examples of suitable systems include copolymers of L-glutamic acid and gamma ethyl-L-glutamate (U.
Sidman et al., 1983, “Biopolymers” 22(l): 547-556), poly (2hydroxyethyl-methacrylate) Langer es al., 1981, Biomed.
Mater. Res.” 15: 167-277 and R. Langer, 1982, “Chem. Tech.” 12: LC8xl72.mdh .4 -36- 98-l05) ethylene vinyl acetate Langer e.t Al., or poly-D- Hydroxybutyric acid (EP 133,988A). Such articles are implanted subcutaneously or are placed into contact with the skin or mucous membranes.
In order to simplify the Examples certain frequently occurring methods will be referenced by shorthand phrases.
Plasmids are designated by a low case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from publicly available 4 plasmids or DNA in accord with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan.
“Digestion” of DNA refers to catalytic cleavage of the DNA with an enzyme that acts only at certain locations in the DNA.
Such enzymes are called restriction enzymes, and the sites for which each is specific is called a restriction site. “Partial” digestion refers to incomplete digestion by a restriction enzyme, conditions are chosen that result in cleavage of some but not all of the sites for a given restriction endonuclease in a DNA substrate. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements as established by the enzyme suppliers were used. Restriction enzymes commonly are designated by abbreviations composed of a capital letter followed by other letters and then, generally, a number representing the microorganism from which each restriction enzyme originally was obtained. In general, about 1 pg of plasmid or DNA fragment is used with about 1 unit of enzyme in about 20 p1 of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer.
Incubation times of about 1 hour at 37’C are ordinarily used, but LC8x172 .mdh -37- Ii, may vary in accordance with the supplier’s instruttions. After incubation, protein is removed by extraction with phenol and chloroform, and the digested nucleic acid is recovered from the aqueous fraction by precipitation with ethanol. Digestion with a restriction enzyme infrequently is followed with bacterial alkaline phosphatase hydrolysis of the terminal 5’ phosphates to prevent the two restriction cleaved ends of a DNA fragment from “circularizing” or forming a closed loop that would impede insertion of another DNA fragment at the restriction site. Unless otherwise stated, digestion of plasmids is not followed by terminal dephosphorylation. Procedures and reagents for dephosphorylation are conventional Maniatis ILIa., 1982, Molecular Cloning pp. 133-134).
‘Recovery” or “isolation” of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide gel electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see R.
Lawn I Al., 1981, “Nucleic Acids Res.” 9: 6103-6114, and D.
Goeddel 1 1980, “Nucleic Acids Res.” 1: 4057.
U 25 ‘Southern Analysis” is a method by which the presence of DNA ;equences in a digest or DNA-containing composition is confirmed by hybridization to a known, labelled oligonucleotide or DNA fragment. For the purposes herein, unless otherwise provided, Southern analysis shall mean separation of digests on 1 percent agarose, denaturation and transfer to nitrocellulose by the method of E. Southern, 1975, Mol. Biol.” 2: 503-517, and hybridization as described by T. Maniatis f 1978, ‘Cell” 687-701.
“Transformation” means introducing DNA into an organism LC8x172.udh i4 -38so that the DNA is replicable, either as an extrachromosomal element or chromosomal integrant. Unless otherwise provided, the method used herein for transformation of 9. 1ol is the CaC1 2 method of Mandel et al., 1970, Mol. Biol.” 5: 154.
t “Ligation” refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments Maniatis et Al., Id., p. 146). Unless otherwise provided, 11gation may be accomplished using known buffers and conditions with 10 units of T4 DNA ligase (“ligase”) per 0.5 pg of approximately equimolar amounts of the DNA fragments to be ligated.
“Preparation” of DNA from transformants means isolating plasmid DNA from microbial culture. Unless otherwise provided, the alkaline/SDS method of Maniatis et Al., Id. p. 90., may be used.
“Oligonucleotides” are short length single or double stranded polydeoxynucleotides which are chemically synthesized by known methods and then purified on polyacrylamide gels.
All citations are expressly incorporated by reference.
EXAMPLE 1 Isolation Of Cloned Inhibin a-Subunit cDNAs The strategy for identification of clones containing coding sequences for the porcine inhibin subunits was based on the “long-probe” approach, successful in some previous instances (Anderson It al., 1983, “Proc. Nat. Acad. Sci. USA” Q:6836-6842 and Ullrich er Al., 1984, “Nature” 1q3:418-425). Briefly, a highcomplexity cDNA library constructed in XgtlO and derived from porcine ovarian mRNA by oligo-dT-primed cDNA synthesis was screened with a single 64-base-long synthetic oligodeoxynucleotide LC8x172.mdh -39directed against the N-terminal amino acid sequence of the a-chain of porcine inhibin. It was found that the library is to be prepared from fresh ovarian tissue because the inhibin chain mRNA was apparently quite labile. Approximately 1 in 2,000 plaques hybridized with, this probe, and sequence analysis of several hybridizing cloned cDNAs confirmed correct probe identification.
This analysis revealed that none of the characterized cDNAs contained sufficient sequence information to predict the complete structure of the a-chain precursor protein. Rather than analyzing more clones from the same cDNA library, a second library was constructed by 3′ extension on ovarian mRNA of a synthetic oligodeoxynucleotide complementary to a sequenced region encoding a precursor residues 60-64 (Fig. 1A). This library was screened with a suitable restriction fragment from a previously analyzed 1 cDNA and yielded several isolates which specified the remainder of the DNA sequences encoding the N-terminal region of the a precursor. Completeness of the coding sequence was judged from the presence of a long reading frame which specifies the porcine a-chain peptide sequence and starts with a methionine codon i 20 preceded by an in-frame stop codon and followed by a hydrophobic S sequence bearing the hallmarks of a signal peptide. The full sequences for the precursor protein and its cDNA are shown in Fig.
lB. The complete protein including signal peptide has an Mr of consisting of 364 amino acids, of which the C-terminal 134 (Mr “14.5K) constitute the porcine inhibin a-chain. There are several Arg-Arg sequences in the proregion of the precursor, one of them directly preceding the subunit. We believe that this latter pair of basic residues is the processing site for the Sproteolytic release of the a peptide. The deduced precursor sequence predicts two N-linked glycosylation sites, one within the a chain proper.
In addition to the coding region, the cDNA sequence contains a 3′-untranslated sequence of 167 nucleotides, including the canonical AATAAA polyadenylation signal, and a LC8x172.mdh I i i untranslated region, the proper length of which is presently unknown.
The detailed method was as follows: Polyadenylated uRNA was prepared from freshly frozen porcine ovaries (K(aplan t Biochem.” JU: 181-184). An oligo-dT-primed cDNA library of 61 clones in XgtlO (Huynh &s.
g,1984, DNA lonng Tebiae- Ed. D. Clover) was prepared from 5 pg polyA+ mRNA as described by Wood pt “Nature” M~1: I0 330-337 (1984). except that the Z~gRI adaptors used had the sequence 5′ -AATTCACTCGAGACGC-31 3′ screened with 5 a-subunit oligonucleotide
ACCGCCCCTTTCCTTGCCTTGTCCCCTGCTGCTCTGAGACTGCTGCAGAGACCTCCT(.AGG-
based on the amino acid sequence underlined in Fig. 1B.
Hybridization was carried out with the phosphorylated 32 p-labfclled probe in 5xSSC, 40% formamide at 37*C. Filters were washed at 50*C with lxSSC, 0.1% SDS. Approximately 500 hybridization positive clones were obtained, twelve of which were purified and examined for insert size. The I&QRl inserts of five of these (APIN-a2, a5A, -aS, -a9, -a10) were subcloned into M13 derivatives (Kessing tj 21l.. 1981 *NucI. Acids Res.* 9:309-321) sequenced by the dideoxy chain termination method of Sanger t Al.,Proc. Nat. Acad. Sci. USA” 74:5463-5467 (1977). A specif-clly primed library was prepared by priming 5 pg of polyA mRNA with the oligonucleotide 51-CCCCACAGCATGTCTT-31 (complementary to nucleotides 248-263) and subsequent cloning into Xgtlo. Approximately 2X10 5 clones of the 1×10 6 clones obtained wore screened with the 5′ 1O0bp kRI-pmI fragment prepared from APIN-a2. Twelve of the 170 hybridization positive clones obtained were purified and two (XPIN-Sl2s, -S4s) were sequenced by the dideoxy method. The, complete nucleotide sequences of the asubunit cDNAs were obtained by subeloning various restriction LC~xl72 .mdh -41fragments from the different A isolates into the M13 phage derivatives. Compressions were resolved by the use of deoxyinosine mixes in combination with the coll single stranded binding protein (Pharmacia).
Isolation of Cloned Inhibin B Subunit cDNAS The cDNA sequences encoding the precursors of the inhibin P subunits were obtained from the same cDNA libraries used for the a subunit. Overlapping cDNA clones were isolated by screening first with single long synthetic oligodeoxynucleotide probes based on the two N-terminal p subunit sequences and subsequently with suitable restriction fragments derived from characterized cDNA clones which served as probes for “walking” in both 5′ and 3′ directions (Fig. 2A).
In more detail, approximately 2×10 5 oligo-dT primed ovarian cDNA clonss were screened with the 5′ end labelled PA oligonucleotide, 5′ -AAGAAGCAGTTCTTTTGTTCCTTCAAGGACATTGGCTGGAATGACTGGATCATTGC-3′ based on the amino acid sequence of residues 321-339. Five hybridization positives were obtained, of which three proved to contain PA coding sequences (APIN-PA2, -PA 4
-PA
8 A 5, end 154 bp EcoRI-HindIII (nucleotides 158-297) fragment and a 3′ end 213 bp EcoRI-Pst fragment (nucleotides 1679-1892) derived from APINPA2 were used to screen 2×10 6 oligo-dT primed cDNA clones and 2×10 clones from the a-chain specifically primed library. Out of the sixteen clones analyzed in detail two were found to have longer ends (APIN-PA5s, -PA 2 2 and one clone APIN-PA21 contained the entire 3′-untranslated region. Porcine inhibin Bg subunit cDNA clones were isolated by screening 2×10 5 clones from the specifically primed library with the Pg oligonucleotide
GGCCTGGAGTGTGATGGGAGAACCAACCTGTCCTGCCGCCAGGAATTTTTCATCGATTTCAGGCT-
which was based on the NH 2 -terminal sequence described in Fig.
IA. Positive clones were further screened with the LC8x172 .dh Sr -42oligonucleotide inosine probe 5′-AAITCTATIAAIAAZTGZ-3′ in this sequence stands for inosine), which covers all the possibilities in the non-coding strand for the amino acid sequence QQFFIDF. Two clones (APINPB-Is, -2s) were isolated and sequenced 3 and found to Code for the PB subunit. A 230 bp k&eRI-Sma (nucleotides 21-251) fragment was isolated from APINPB-I and used as a hybridization probe to screen 2×10 6 oligo-dT primed cDNA clones. Two positives were obtained (APINPB-3,4). The nucleotide sequence of these overlapping clones was used to construct the 0 sequence shown. All sequences were obtained by subclonin; specific fragments into M13 phage vectors (Messing et l. o~ gct.). The EcoRI restriction sites referred to above are all contained within the cDNA adaptor fragment, and do not refer to sequences present in the cDNA.
We noted that only very few clones from the oligo-dTprimed library (4 out of 2×10 5 hybridized with the synthetic probe for the #-subunit of inhibin A. Although most of these proved correct by DNA sequence analysis, none contained a full 3’untranslated region, as judged by the absence of a polyA homopolymer at their 3′ ends. Absence of polyA tails suggested the existence of a very long 3′-untranslated sequence in this mRNA species and/or structural region(s) which prove difficult to copy by the polymerases used for library construction. Unexpectedly, a higher abund&;ce (10-fold) of inhibin PA subunit coding sequences was found in the cDNA library made by specific priming on asubunit mRNA. This library was screened with the synthetic probe for the p-chain of inhibin A on the subsequently refuted theory that the a precursor mRNA might also encode the P subunit. The high abundance of inhibin PA cDNA in this library was later traced to fortuitous complementarity of the specific a chain primer to a region in the untranslated portion of the corresponding mRNA.
Only four cloned cDNAs encoding the P subunit of inhibin B were found in our libraries. The sequence information obtained LC8xl72.adh i i -43from these clones “ailed to reveal the complete structure of the corresponding precursor protein and its cDNA. The sequences of cDNAs and deduced protein structures for the precursors of the f subunits are compared in Fig. 2B. The nucleotide sequence of inhibin PA subunit cDNA is.-3.6 kb in length and contains an open reading frame for a protein of 425 amino acids (Mr -46K), the Cterminal 116 residues of which represent the P subunit proper (Mr -13K). This reading frame begins with a methionine codon followed by a sequence that codes for a characteristic signal peptide, the true length of which is believed to be 29 residues. The encoded P subunit is preceded by a string of 5 arginines at which it is presumably proteolytically cleaved from the precursor. Similar to the a subunit precursor, this P precursor contains several additional pairs of basic residues at which hitherto unknown biologically active peptide entities are believed to be released.
It also contains one possible site for N-linked glycosylation in the proregion (Asn, residue 165).
The deduced protein sequence for the P subunit of inhibin B shows high homology with the PA subunit sequence. 71 amino acid residuei are identical and most changes are conservative in nature. Sequence homology, although of a lesser degree, is also found in the proregion of both a subunit precursors. Interestingly, an extremely purine-rich sequence rarely seen in coding regions but present in the cDNA encoding the inhibin PA precursor and resulting in a curious amino acid sequence is not found in the cDNA which codes for the homologous AB precursor. This results in a gap of 22 amino acid residues from the PB precursor of inhibin when protein sequences are aligned for maximal homology. Such alignment also brings about a perfect match in the cysteine positions of both precursors (see Fig. 2B).
LC8x172.mdh
I
Northern Analysis of a and B chain Precursor mRNAS ft I I 44-) 13 1 I ft Ovarian total and polyadenylated RNAs were analyzed by the Northern procedure using the sequenced cDNAs as probes to assess size and relative abundance of the mRNAs which encode the peptide subunits a and P and Pb of the heterodimeric inhibin molecule. Polyadenylated mRNA (2 pg: lanes a, b, c, and f; 8 pg: lane d) and total RNA -(10 pg: lanes e and g) were electrophoresed into a formaldehyde 1.2% agarose gel and blotted onto nitrocellulose filters. The following 32 P-labelled cDNA fragments were used as hybridization probes under stringent conditions. Lane a: 240 bp EcoRI-ISal (nucleotides 134-371) from a subunit cDNA; b: 154 pb EcoRl-HindTII (nicleotides 158-297) ftom PA subunit cDNA; c: 230 bp EcoRI-Sma (nucleotides 21-251) from PB subunit cDNA; d and e: EcoRI insert of APIN-a2; f and g: EcoRI insert of Filters were washed for 2 hours with 3 changes of O.IxSSC, 0.1% SDS at Analysis showed (Fig. 3) that a and mRNAs are of differen’y size and abundance, as indicated by results obtained from cDNA cloning. From their respective band intensities the a precursor mRNA is estimated to be at least of 10-fold higher abundance than the mRNA for the PA precursor, and approximately higher than the mRNA for the PB precursor.
Using ribosomal RNAs as size standards, the a precursor mRNA, which is a single species, is “1500 nucleotides in length, a size in good agreement with the cloned cDNA sequence (Fig. 1B).
PA precursor mRNA sequences are represented by two main species of and “7.2 kb in length. The relatively higher intensity of both species in polyadenylated than total RNA suggests that the kb species does not represent 28S RNA which hybridized to the cDNA probe. Thus, the A precursor cDNA sequences shown in Fig. 2, are thought to represent the 4.5 kb mRNA, suggesting that the untranslated region for the PA mRNA is approximately 900 LC8x172.mdh nucleotides long. The pg precursor is encoded on one mRNA. of approximately 4.5 kb in size, which is present at roughly half the level of the two #A mRNAs. Since the two P mRNAs are closely i related, one can predict that both mRNAs have a similar structure and thus the Bg mRNA presumably possesses a long 5′ and 3′ untranslated region equivalent to that shown for the PA mRNA.
Choice of a different polyadenylation signal might explain the existence of the 7.2 kb species.
Homology To Transforming Growth Factor-B The mature a and p inhibin subunits contain seven and nine cysteine residues respectively. Upon alignment of the cysteine residues it is apparent that the two subunits share a similar cysteine distribution and some sequence homology exists around these residues (Fig. suggesting that both types of subunits derive from one ancestral gene. Surprisingly, significant homology was found between the p chain and the primary structure of human TGF-P recently determined. As outlined in Fig.
4, both peptides are of nearly equal length (inhibin PA subunit, 116; SB subnit 115; TGFS, 116 residues) and show a strikingly similar distribution of their nine cysteine residues. Using this cysteine “skeleton” for alignment, the A and TGF-A sequences have an additional 31 residues in identical positions and show conservative changes in nine homologous places. Similar high homologies are seen upon comparison of the PB and P-TGF. Some gaps were introduced for better alignment (Fig. The overall homology reaches 35%, but approaches 60% in certain sections (cf.
Sporcine inhibin #A chain residues 11-45 and TGF residues 15-49), a very high degree of homology considering the difference in species. Interestingly, this homology extends beyond the termination codon for protein synthesis in the respective cDNAs.
Thus, the cDNAs for TGF-P and both inhibin P subunits contain a highly G and C rich sequence in this region, and they also possess unusually long 5′ and 3′ untranslated regions.
1 LC8x172.mdh -46- One can discount the suggestion that the B subunit of inhibin is the porcine equivalent of human TGF-P, since there is almost absolute homology between human and murine P-TGFs. These findings strongly indicate-that both inhibin subunits and TGF-p have a common ancestor and belong to one gene family. All three peptides are derived from similarly-sized precursors (Mr where they occupy the C-terminal 110 or so residues and are released by proteolytic cleavage at pairs of arginines. They form homo- or heterodimers, and subunits in the biologically active complex are linked by disulfide bridges. However, there is little sequence homology between TGF-3 and the P subunits in the pro j parts of their precursors, although the regions comprising the odd residues which precede tho P subunit and TGF peptides display S limited but significant sequence relatedness.
EXAMPLE 2 V Recombinant Synthesis of Porcine Inhibin The plasmid used for recombinant synthesis of porcine inhibin was pSVE-PaBAInh-DHFR. The procedure to construct this plasmid is shown in Fig.5. This plasmid was constructed as follows: pHBS348-E (EP 0073656A) was partially digested with EcoRI, blunted with &l DNA polymerase I (Klenow fragment) and the four dNTPs, ligated and the ligation mixture was transformed into E. coli in 294 (ATCC 31446). The transformed culture was plated on ampicillin media plates and resistant colonies selected.
li 30 Plasmids are screened for the loss of the EcoRI site preceding the early promoter. A plasmid having the site deleted is referred to as pHBS348-EII.
pHBS348-EII was digested with EcoRI and EcoRI to produce two fragments, fragment I containing the SV40 early promoter, pmL- LC8x172.mdh -47t tf Amp- sequences and the HBsAg 3′ untranslated region and fragment 2 containing the HBsAg (hepatitis B antigen) coding sequences.
containing the coding region for the porcine inhibin #A subunt was digested with EcoRI and SmaI and the 1335 bp fragment (fragment 3) containing the PA coding region recovered by polyacrylamide gel electrophoresis. Fragment I, recovered by agarose gel electrophoresis, was ligated to fragment 3 and the ligation mixture transformed into E. poll strain 294 (ATCC 31446).
The transformed culture was plated on ampicillin media plates and resistant colonies selected. Plasmid DNA was prepared from transformants and checked by restriction analysis for the presence of the correct DNA fragments. This plasmid is referred to as pSVE-p#AInh.
pHBS348-E (EP 0073656A) was partially digested with EcoRI, blunted with ~1co DNA polymerase I (Klenow fragment) and the four dNTPs, ligated to the synthetic oligonucleotide GGTCGACC-3′ containing the SalI recognition site. The transformed culture was plated on ampicillin media plates and resistant colonies selected. Plasmids were screened for the presence of the extra SalI restriction site. Plasmid DNA is prepared from this construction (pHBS348-ESalI).
APINa-12s and APINa-2 were digested with EcoRI and &AmHI. A 104 bO ERI-amHI fragment from APINa-12s containing the coding region and a 1246 bp EcoRI-BMlHI fragment from APINa-2 containing the middle and 3′ coding region were recovered and ligated together. The ligation mixture was digested with EcoRI, the enzyme heat denatured, and the mixture ligated to EcoRIdigested pUC9 (BRL). Recombinants were selected and confirmed by restriction analysis. DNA was prepared from the correct plasmid (pPINa).
pPINa, containing the complete coding region for porcine LC8x172.mdh
I
-48a-inhibin was digested with PoI and EcoRI, filled in by Pol(I)K in the presence of 4dNTP’s, the 1280 bp fragment (fragment 4) was recovered by gel electrophoresis. pHBS348-ESalI was digested with SSsll and =indIII, filled in by Pol(I)K in the presence of 4dNTP’s, and fragment 5 containing the PML-Ampr region, SV40 early promoter and HBsAg 3′ untranslated region was recovered by gel electrophoresis. Fragments 4 and 5 were ligated together and the ligation mixture used to transform E. coli 294 (ATCC 31446).
Recombinants were selected by growing on Ampicillin media plates.
The desired recombinant is called pSVE-PaInh.
pHBS348-ESallI was digested with gall and HindIII and fragment 6 containing the pML-Ampr, and SV40 early promoter was recovered by gel electrophoresis. pFD II (EP 117,060A) was digested with SalI and HindIII and fragment 7 was recovered which contains the normal mouse DHFR gene fused to the HBsAg 3′ untranslated region. Fragments 6 and 7 were ligated, and the ligation mixture transformed into E. ~oi strain 294 (ATCC 31446).
The transformed culture was plated on empicillin media plates and resistant colonies selected. Plasmid DNA was prepared from transformants and checked by restriction analysis for the presence of the correct DNA fragments. This construction is referred to as pFDII-Sall.
pSVE-PaInh was digested with SAIl and fragment 8 was recovered which contains the SV40 early promoter and the a-inhibin coding region fused to the HBsAg 3′-untranslated region. pFDII- Sall was digested with Sall and fragment 9 containing the early promoter and the mouse DHFR coding region linked to the HBsAg 3’-untranslated region was recovered. pSVE-PAInh was linearized by SJll digestion and ligated to fragments 8 and 9 in a three part ligation. The ligation mixture was transformed into E.
SUl strain 294 (ATCC 31446). The transformed culture is plated on ampicillin media plates and resistant colonies selected.
Transformants were screened for the presence of fragments 8 and 9 LC8x172.udh I ,i~4 ii Itl i Is d 20 -49in the correct orientation such that transcription from the three early promoters will proceed in the same direction. This final plasmid is designated pSVE-PaAInh-DHFR.
Plasmi4 pSVE-Pa8AInh 7HFR was transfected into DHFR deficient CHO cells (Urlaub and Chasin, 1980, PNAS 77,4216-4220).
However, any DHFR” mammalian host cell is suitable for use with this plasmid. Alternatively, any mammalian host cell is useful when the host cell is cotransformed with a plasmid encoding neomycin resistance, and transformants identified by their ability to grow in neomycin-containing medium.
The transfected CHO cells were seleccad by culturing in HGT” medium. The cells were allowed to grow to confluency in 15cm diameter plates. The cells thereafter were cultured in serum free medium for 48 hours prior to harvest. 50ml of supernatant medium was lyophilized after the addition of 100mg human serum albumin. The residue was redissolved in 3ml 1% fetal bovine serum in HDMEM (GIBCO Laboratories, Santa Clara, CA), filtered through a Millex-GS 0.22mM filter (Millipore Corp., Bedford, MA) and assayed in duplicate.
The inhibin hormonal activity in the transformant supernatants was determined by an in vitro bioassay using rat anterior pituitary monolayer culture, Vale, W. et al.
Endocrinology, 21, 562-572 (1972). In brief, 21-day-old female rat anterior pituitaries were collected, enzymatically dispersed and plated in 10% fetal bovine serum in HDMEM (GIBCO Laboratories, Santa Clara, CA) into 24-well tissue culture plates (Falcon Plastic, Oxnard, CA) on day 1. On day 2, the medium was changed to 1% fetal bovine serum in HDMEM, and the transformant medium sample was added. Incubation was continued for another 48 hours.
The monolayer medium was then harvested, and the LH and FSH contents were determined by radio-immunoassay (RIA) using materials provided by The Pituitary Hormone Program of NIADDKD.
LC8x172.mdh In this assay, the inhibin-containing CHO cell culture inhibits the basal release of FSH but not LH, as compared to control pituitary cells that received the incuhbtion medium only. The amount of porcine inhibin detected in transformant supernatants was 20 ng/ml and,exhibited” dose response curve parallel to that obtained with pure porcine ovarian inhibin.
Immunological cross-reactivity is assayed by a sandwichtype radioimmunoassay. Rabbit antisera are raised against purified porcine follicular inhibin by s,c. immunization of rabbits with the porcine inhibin in Freund’s complete adjuvant.
The presence of anti-inhibin in the antiserum is detected by incubation of the antiserum with purified porcine inhibin and assaying for the formation of an immune complex by conventional
I
techniques, e.g. gel filtration. An aliquot of the antisera is coated onto goat-anti-rabbit IgG precoated polystyrene test tubes.
The recombinant culture supernatant or extract is diluted into phosphate buffered saline and added to the coated tubes, incubated overnight and washed. Another aliquot of the rabbit antiserum is added to the test tubes, incubated and washed. Radioiodinated goat antirabbit IgG is added to the tubes, incubated and unbound goat antiserum removed by washing. The recombinantly produced inhibin cross-reacts with the rabbit antiserum, as evidenced by bound counts on the test tubes which exceed those of controls incubated with culture medium or extracts from untransformed host cells.
SEXAMPLE 3 Construction of Human nhibin Vector and Expression of Human Inhibin in I Recombinant Cellaulture-1 Expression of human inhibin aPA is facilitated by the discovery that the mature porcine and human PA chains are identical. Thus, construction of a vector for the expression of LC8x172.mdh -r -51human inhibin can proceed from plasmid pSVE-PA-Inh from Example 1, which contains the porcine PA-encoding cDNA.
I
Ti
I
}f
J
A Agt 10 library of human ovarian cDNA made from 10 ig of ovarian ‘mRNA was iubjected to Southern analysis using radiophosphate labelled porcine cDNA encoding a, #A and PB chains.
AHINa-2 was identified as containing coding regions for the human a inhibin chain. The prevalence of hybridizing clones in the case of human a inhibin was considerably less than that found for porcine a inhibin, on the order of 1 in 100,000 human clones hybridized to the 685 bp Smal fragment of the porcine cDNA for aInh. The P chain clones were also rare, with the PB clones being present at about 3 times the level of PA (1 and 3 out of about 1,000,000 clones, respectively). None of the p chain clones were full length. They were supplemented with a primed cDNA library and assembled generally as described above for the porcine cDNA.
The A inserts were recovered by EcoR1 digestion.
Plasmid pHINa-2 is digested with NcoI and SmaI, and the 1049 bp 15 fragment (fragment 10) is recovered by gel electrophoresis. pPina (Example 2) is digested with EcoRI and vuII. The 98 bp fragment (fragment 11) is recovered by gel electrophoresis. Fragments 10 and 11 are ligated to adaptor I CTGCTCCTCTTGCTGTTGGCCCCACGGAGTGGGCATGGCTGCCAGGGCCCGGAGCTGGACC-3′, in combination with adaptor II which is the complement of adaptor I. The resulting 1208 bp fragment (fragment 12) is treated with Klenow fragment of Pol(I) and the 4 dNTP’s and ligated to pHBS348- ESall which has been restricted with HindIII and SacII and bluntended as described in Example 1. Alternatively, pPina was digested with EcoRI and HpaII with the fragment encoding upstream from the HpaII site (that is, the first 21 residues of the porcine sequence) being recovered. The adaptor used in this alternative approach was 5’CGGAGCTCGACC 3′ 3′ CTCGAGCTGG LC8xl72.mdh -52- A plasmid pSVE-HaInh having the correct orientation of fragment 12 is identified by sequence analysis of transformants. This construction (pSVE-HaInh) thus contains the first 24 residues of the porcine signal sequence with the remainder being prepro human inhibin. Plasmid pSVE-HaInh is digested with SAI. The fragment V containing the SV40 promoter and human inhibin sequence is ligated to fragment 9 and Sall digested pSVE-PAInh (Example This final plasmid designated pSVE-hapAInh-DHFRl is transfected into DHFR-deficient CHO cells and selected as described in Example 2.
The culture supernatant contains hormonally active human inhibin.
EXAMPLE 4 Construction of Human Inhibin Vector I and Expression of Human Inhibin 1 in Recombinant Cell Culture-II This example is similar to Example 3 except that the pro sequence of human inhibin PB was employed in the place of the porcine AB prepro domain.
The lambda gtlO library of Example 3 yielded AHINa2, as described in example 3, together with XHINAA-5 and -14. The latter two phage were employed to construct the full length pA coding cDNA by ligating the 311 bp EcoRl-HindIII fragment (fragment 13) of AHINAA-5 to the 1101 bp HindIII-Hpal fragment (fragment 14) of AHINPA-14 and ligating this mixture in an EcoRl- SalI digested mpl8 vector (Biolabs). Clone were selected and screened for the appropriate sized insert. An mpl8 vector containing the correct insert was treated with DNA polymerase(I) and the four dNTPs in order to render it double stranded, and thereafter digested with kXal (which cleaves in the mpl8 polylinker sequence), blunted with DNA polymerase I and the four dNTPs, and digested with EcoR1. A 1320 bp fragment (fragment was ligated to the E2Rl-EcoRV fragment 1 from Example 2. This ligation mixture was used to transform E. coli 294 cells. Clones LC8x172 .mdh I- -53were screened by Southern Hybridization and confirmed by i restriction analysis. The clone containing the hInhPA coding sequence was designated pSVE-humAInh. A plasmid containing the i human PA coding sequences and the human a-inhibin sequences I together with th’e DHFR gehe is constructed from plasmids pSVEhumpAInh, pSVE-HaInh and pFDIISalI as outlined above.
Specifically, the Sal fragments from pSVE-HaInh and pFDIISall which contain the human alpha inhibin and the DHFR genes were ligated with gall digested pSVE-humSAlh and a clone containing all three genes was identified. This plasmid, designated pSVEhumafAInh-DHFR2 was transfected into DHFR” CHO cells and selected by culture in ght” medium. 24 clones were picked, grown to confluency in ght” medium under conditions conventional for CHO 3 cells for two days, allowed to rest for 2 more days and thereafter the culture media were assayed for inhibin and activin activity using the rat pituitary cell assay described above. 4 clones were found to secrete significant levels of human aOA inhibin (ha/A-B, 12, 14, and 18). The levels in the culture medium for each clone were, respectively, 125, 125, 200 and 250 ng/ml. Another clone (hPA-l11) produced activin as the PAPA homodimer, but no detectable inhibin, as determined by biological activity and the lack of a chain immunoreactivity in the culture medium for this clone. Clone haPA-1 6 secreted only a chain and was devoid of activin or inhibin activity.
EXAMPLE Recombinant Expression of Human Activin As reported by Vale et al. and Ling St al. homodimers and heterodimers of, the 6 chains A and/or B have the opposite effect of inhibin on the pituitary, inducing rather than inhibiting FSH secretion. These proteins, collectively termed activin, are made in a and P chain cotransformants as described in Example 4. However, somewhat less screening for an appropriate transformant is needed if the initial transfection is conducted LC8x172.mdh I -54with a vector or vectors that do not contain the a chain gene. A suitable vector is readily constructed from the above-described vectors by excising the a chain gene. Plasmid pSVE-humpAInh from j Example 4 is digested with ail and ligated to fragment 9 (Example 2) containing the DHFR gene. The ligation mixture was used to transfect E. coli 294 cells and colonies selected on the basis of I failure to hybridize to the a chain sequence but which did hybridize to the p chain DNA. A clone pSVE-humPAInh-DHFR was identified from which the a chain DNA had been deleted. This clone is transfected into DHFR’ CHO cells as described “bove.
Transformants are identified that secrete activin into the culture medium. Similarly, an expression vector containing a OB coding sequence (reconstituted by ligating DNA encoding the first 34 Samino acids of human 8A to the remaining coding sequence of the Shuman PB chain) is readily constructed and cotransfected with SpSVE-humPAInh-DHFR to produce the heterodimer. The reconstructed human PB gene also is used in the forgoing plasmids in order to produce paB-inhibin which, in the in vitro bioassay has j essentially equivalent biological potency to the aPA form of S2 inhibin.
-i SAlthough the invention has been described with regard to its preferred embodiments, which cqnstitute the best mode o presently known to the inventors, it should be understood that various changes and modifications as would be obvious to one having the ordinary skill in the art may be made without departing from the scope of the invention which is set forth in the claims appended hereto.
LC8x172 .dh

Claims (21)

1. A method comprising constructing a vector which includes nucleic acid encoding inhibin a chain or an inhibin p chain or both inhibin a and inhibin p chains of human or pnrcine inhibin transforming a host cell with the vector, and culturing the transformed cell.

2. The method of claim 1 wherein the nucleic acid encoding the human or porcine inhibin a chain or p chain is operably linked to a promoter recognized by the host cell and including the further step of recovering inhibin or a p chain dimer from the culture medium.

3. The method of claim 1 wherein the cell is a prokaryote.

4. The method of claim 1 wherein the vector comprises nucleic acid encoding the prepro forms of both the human or porcine inhibin a chain and inhibin p chain. The method of claim 2 wherein the cell is a cell from a multicellular organism and the inhibin is hormonally active.

6. The method of claim 2 wherein the promoter is a viral promoter.

7. The method of claim 6 wherein the promoter is an promoter.

8. The method of claim 2 wherein the vector comprises nucleic acid encoding the prepro form of human or porcine inhibin p chain and a mature p-chain dimer is recovered free of the a-chain.

9. The method of claim 5 wherein the p chain is the PA chain of human or porcine inhibin as hereinbefore defined and the inhibin is present in a concentration greater than about 10 ng/ml in the culture medium. The method of clL.m 1 wherein the nucleic acid encodes an amino acid sequence variant of the human or porcine inhibin a or p chain.

11. Recombinant human or porcine inhibin which is completely free of unidentified human or porcine UL U0 -q 4,P ASSP3.06,6351286. I -4 56 proteins.

12. Recombinant human or porcine a or p, inhibin i prodomain as hereinbefore defined unassociated with I native glycosylation.

13. A recombinant homodimer of mature human or porcine inhibin PA or p, chains as hereinbefore defined, which is free of the inhibin a chain.

14. A recombinant heterodimer of mature human or porcine inhibin P, with mature inhibin P, as defined i herein, which is free of the inhibin a chain. Isolated DNA encoding a biologically active human or porcine inhibin a or inhibin p chain. t, 16. The DNA of claim 15 which is free of Sintervening untranslated sequences.

17. The DNA of claim 15 which is labelled with a detectable moiety. S 18. The DNA of claim 15 which encodes an amino acid sequence variant of the a or p chain of human or porcine inhibin.

19. A replicable vector comprising DNA encoding an inhibin a or p chain or both inhibin a and inhibin p chains of human or porcine inhibin. The vector of claim 19 comprising a viral promoter operably linked to the DNA encoding the human or porcine inhibin a or p chains.

21. The vector of claim 19 which contains DNA encoding both human or porcine inhibin a and an inhibin p chain. it 22. The vector of claim 20 which contains DNA encoding a human or porcine inhibin p chain but not the Sinhibin a chain. J 23. A host cell transformed with a replicable vector comprising DNA encoding the human or porcine inhibin a or an inhibin p chain.

24. The cell of claim 23 which is a eukaryotic cell. L 25. A human or porcine inhibin a chain prodomain 814,PASSPE006.63512-86.cm,56 _.J 57 sequence that is free of mature a chain sequence.

26. A recombinant polypeptide selected from: a) a polypeptide comprising the human inhibin P, chain prodomain sequence HSAAPDCPSCALAALPKDVPNSQPEMVEAVKK- HILNMLHL, PDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIG, AEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTR- TKVTIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDA, STWHVFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLG, or naturally occurring mammalian amino acid sequence variants thereof as hereinbefore defined; b) a polypeptide comprising the human inhibin P, chain predomain sequence CTSCGGFRRPEELGRVDGDFLEAV, HILSRLQMRGRPNITHAVPKAAMVTALRKLHAGKVREDGRVEIPHLDGHASPGADGQE- RVSEIISFAETDGLASSRVRLYFFISNEGNQNLFVVQASLWLYLKLLPYVLEKGS, VRVKVYFQEQGHGDRWNMVEKRVDLKRSGWHTFPLTEAIQALFERGE, LNLDVQCDSCQELAVVPVFVDPGEESHRPFVVVCRGDSRHRI, or naturally occurring mammalian amino acid sequence variants thereof as hereinbefore defined; or c) a polypeptide free of the mature a chain amino acid sequence comprising the human inhibin a chain prodomain sequences KVRALFLDALGPPAVTREGGDPGV, HALGGFTHRGSEPEEEEDVSQAILFPATDASCEDKSAARGLAQEAEEGLFRYMFRPSQ- HTRSRQVTSAQLWFHTGLDRQGTAASNSSEPLLGLLALSPGGPVAVPMSLGHAPPHWA- SVLHLATSALSLLTHPVLVLLLRCPLCTCSARPEATPFLVAHTRTRPPSGGERA, or naturally occurring mammalian amino acid sequence variants thereof as hereinbefore defined.

27. A human or porcine inhibin p chain prodomain sequence.

28. The p chain of claim 27 which is the P, chain or human or porcine inhibin as hereinbefore defined and which is free of mature PA chain sequence.

29. The P chain of claim 27 which is the P, chain as hereinbefore defined and which is free of mature P, chain sequence. The recombinant polypeptide of claim 26 wherein the variant is the corresponding porcine amino acid sequence.

512-86.clm,57 58 31. The recombinant polypeptide of claim 26 wherein the polypeptide is unaccompanied by native glycosylation. 32. The recombinant polypeptide of claim 26 which is sterile and wherein the polypeptide further comprises an immunogenic polypeptide. 33. An antibody capable of binding a predetermined polypeptide of claim 26. 34. The recombinant polypeptide of claim 26 wherein the polypeptide is conjugated to a detectable group. The recombinant polypeptide of claim 34 wherein the group is an enzyme, fluorophore or radioisotope. 36. The recombinant polypeptide of claim 26,which is o0, insolubilized by non-covalent adsorption or covalent cross- as. linking to a water insoluble support. o 37. The recombinant polypeptide of claim 26 further 0a comprising a physiologically acceptable implantable matrix for controlled release of the polypeptide into the tissues 0o n of an animal. DATED this 17th day of August, 1990 GENENTECH, INC. o’O0 by its Patent Attorneys “oe DAVIES COLLISON o 0 S o

AU63512/86A
1985-10-03
1986-10-02
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

Expired

AU603775B2
(en)

Applications Claiming Priority (6)

Application Number
Priority Date
Filing Date
Title

US78391085A

1985-10-03
1985-10-03

US783910

1985-10-03

US82771086A

1986-02-07
1986-02-07

US827710

1986-02-07

US06/906,729

US4798885A
(en)

1986-02-07
1986-09-12
Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain

US906729

1986-09-12

Related Child Applications (1)

Application Number
Title
Priority Date
Filing Date

AU54651/90A
Division

AU5465190A
(en)

1985-10-03
1990-05-03
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

Publications (2)

Publication Number
Publication Date

AU6351286A

AU6351286A
(en)

1987-04-09

AU603775B2
true

AU603775B2
(en)

1990-11-29

Family
ID=27419805
Family Applications (3)

Application Number
Title
Priority Date
Filing Date

AU63512/86A
Expired

AU603775B2
(en)

1985-10-03
1986-10-02
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

AU54651/90A
Abandoned

AU5465190A
(en)

1985-10-03
1990-05-03
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

AU52433/93A
Abandoned

AU5243393A
(en)

1985-10-03
1993-12-15
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

Family Applications After (2)

Application Number
Title
Priority Date
Filing Date

AU54651/90A
Abandoned

AU5465190A
(en)

1985-10-03
1990-05-03
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

AU52433/93A
Abandoned

AU5243393A
(en)

1985-10-03
1993-12-15
Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

Country Status (11)

Country
Link

EP
(1)

EP0222491B2
(en)

AT
(1)

ATE119937T1
(en)

AU
(3)

AU603775B2
(en)

CA
(1)

CA1341631C
(en)

DE
(1)

DE3650267T3
(en)

ES
(1)

ES2072248T5
(en)

HK
(1)

HK1007332A1
(en)

IE
(1)

IE65795B1
(en)

IL
(1)

IL80218A
(en)

LV
(1)

LV11485B
(en)

NZ
(2)

NZ231899A
(en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU610821B2
(en)

*

1985-04-18
1991-05-30
Inhibin Pty Limited
Recombinant inhibin

DE3650689T2
(en)

1985-04-18
1999-04-08
Biotech Australia Pty Ltd

RECOMBINANT INHIBIN

JPH0637520B2
(en)

*

1985-07-03
1994-05-18
味の素株式会社

Polypeptide

US4740587A
(en)

*

1985-07-18
1988-04-26
The Salk Institute For Biological Studies
Inhibin and method of purifying same

WO1987005702A1
(en)

*

1986-03-13
1987-09-24
Biotechnology Australia Pty. Ltd.
Method of assay of inhibin

CA1302651C
(en)

*

1986-04-04
1992-06-02
Wylie Walker Vale, Jr.
Fsh-releasing peptide

US4973577A
(en)

*

1986-04-04
1990-11-27
The Salk Institute For Biological Studies
FSH-releasing peptides

US5015729A
(en)

*

1986-06-24
1991-05-14
The Salk Institute For Biological Studies
Ovine inhibin

ATE118351T1
(en)

*

1988-05-31
1995-03-15
Biotech Australia Pty Ltd

EFFECT OF HORMONES.

US5071834A
(en)

*

1988-09-16
1991-12-10
Genentech, Inc.
Purified activin B composition

US4997815A
(en)

*

1988-11-01
1991-03-05
Children’s Hospital Medical Center Of Northern California
Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin

AU7321891A
(en)

*

1990-02-15
1991-09-03
Cetus Corporation
Inhibitor of cytokine activity and applications thereof

IL99867A0
(en)

*

1991-10-27
1992-08-18
Yissum Res Dev Co
Pharmaceutical compositions containing activin a

JP3504263B2
(en)

1991-11-04
2004-03-08
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー

Recombinant bone morphogenetic protein heterodimers, compositions and uses

US5807713A
(en)

*

1992-02-12
1998-09-15
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung
DNA encoding growth/differentiation factor

US6120760A
(en)

*

1992-02-12
2000-09-19
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung
Growth/differentiation factors of the TGF-β family

US7067637B1
(en)

1992-02-12
2006-06-27
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh
Antibody or antibody fragments specific for a protein of the TGF-β family

US7025959B1
(en)

1992-02-12
2006-04-11
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh
MP121, a growth/differentiation factor of the TGF-β family

US6171584B1
(en)

1992-02-12
2001-01-09
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh
Method of treatment with growth/differentiation factors of the TGF-β family

US5753612A
(en)

*

1992-10-27
1998-05-19
Yissum Research Development Co. Of The Hebrew University Of Jerusalem
Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists

PT1378572E
(en)

*

1993-05-12
2007-01-31
Genetics Inst
Bmp-11 compositions

US5658876A
(en)

*

1994-04-28
1997-08-19
The General Hospital Corporation
Activin antagonists as novel contraceptives

FR2720069A1
(en)

*

1994-05-19
1995-11-24
Inst Nat Sante Rech Med
Variants of transforming growth factor-beta proteins

IL114397A0
(en)

*

1994-07-01
1995-10-31
Bioph Biotech Entw Pharm Gmbh
Growth/differentiation factor of the TGF-beta-family

EP1163365A4
(en)

1999-02-25
2002-11-20
Auckland Uniservices Ltd
Diagnosis and therapy of premature ovarian failure

TWI329129B
(en)

2001-02-08
2010-08-21
Wyeth Corp
Modified and stabilized gdf propeptides and uses thereof

AUPR638101A0
(en)

2001-07-13
2001-08-09
Bioa Pty Limited
Composition and method for treatment of disease

PL1675608T3
(en)

2003-09-12
2007-11-30
Wyeth Corp
Injectable calcium phosphate solid rods for delivery of osteogenic proteins

WO2005116052A2
(en)

2004-04-27
2005-12-08
Research Development Foundation
ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING

TWI610939B
(en)

*

2007-02-21
2018-01-11
腫瘤療法 科學股份有限公司
Peptide vaccines for cancers expressing tumor-associated antigens

TW201008574A
(en)

2008-08-19
2010-03-01
Oncotherapy Science Inc
INHBB epitope peptides and vaccines containing the same

WO2010144696A1
(en)

2009-06-11
2010-12-16
Burnham Institute For Medical Research
Directed differentiation of stem cells

BR102014005376A2
(en)

*

2014-03-07
2016-02-10
Ouro Fino Saúde Animal Ltda

inhibin alpha antigen, inhibin alpha coding gene, fusion protein encoding gene, process of obtaining inhibin alpha antigen, antigenic composition, use of inhibin alpha antigen, and use of antigenic composition

CN108285903B
(en)

*

2018-01-29
2021-03-12
国家卫生计生委科学技术研究所
Preparation method of specific stimulating antigen

Citations (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU5903986A
(en)

*

1985-04-18
1986-11-05

Biotechnology Australia Proprietary Limited

Recombinant inhibin

AU7101587A
(en)

*

1985-04-18
1987-06-25

Inhibin Pty Limited

Recombinant inhibin

Family Cites Families (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

CA1341617C
(en)

*

1984-06-08
2011-06-28
Henry George Burger
Inhibin isolated from ovarian follicular fluid

DE3650689T2
(en)

*

1985-04-18
1999-04-08
Biotech Australia Pty Ltd

RECOMBINANT INHIBIN

1986

1986-09-29
NZ
NZ231899A
patent/NZ231899A/en
unknown

1986-09-29
NZ
NZ217727A
patent/NZ217727A/en
unknown

1986-10-02
EP
EP86307586A
patent/EP0222491B2/en
not_active
Expired – Lifetime

1986-10-02
IE
IE261886A
patent/IE65795B1/en
not_active
IP Right Cessation

1986-10-02
DE
DE3650267T
patent/DE3650267T3/en
not_active
Expired – Lifetime

1986-10-02
IL
IL8021886A
patent/IL80218A/en
not_active
IP Right Cessation

1986-10-02
ES
ES86307586T
patent/ES2072248T5/en
not_active
Expired – Lifetime

1986-10-02
AT
AT86307586T
patent/ATE119937T1/en
not_active
IP Right Cessation

1986-10-02
AU
AU63512/86A
patent/AU603775B2/en
not_active
Expired

1986-10-03
CA
CA519750A
patent/CA1341631C/en
not_active
Expired – Fee Related

1990

1990-05-03
AU
AU54651/90A
patent/AU5465190A/en
not_active
Abandoned

1993

1993-12-15
AU
AU52433/93A
patent/AU5243393A/en
not_active
Abandoned

1996

1996-03-14
LV
LVP-96-83A
patent/LV11485B/en
unknown

1998

1998-06-25
HK
HK98106550A
patent/HK1007332A1/en
not_active
IP Right Cessation

Patent Citations (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU5903986A
(en)

*

1985-04-18
1986-11-05
Biotechnology Australia Proprietary Limited
Recombinant inhibin

AU7101587A
(en)

*

1985-04-18
1987-06-25
Inhibin Pty Limited
Recombinant inhibin

Also Published As

Publication number
Publication date

AU6351286A
(en)

1987-04-09

DE3650267T2
(en)

1995-10-05

CA1341631C
(en)

2012-06-12

LV11485B
(en)

1996-12-20

EP0222491B1
(en)

1995-03-15

IE862618L
(en)

1987-04-03

EP0222491A1
(en)

1987-05-20

DE3650267D1
(en)

1995-04-20

LV11485A
(en)

1996-08-20

EP0222491B2
(en)

2003-08-13

HK1007332A1
(en)

1999-04-09

AU5243393A
(en)

1994-03-10

ES2072248T5
(en)

2004-05-01

ES2072248T3
(en)

1995-07-16

NZ217727A
(en)

1990-05-28

IE65795B1
(en)

1995-11-15

DE3650267T3
(en)

2004-05-13

NZ231899A
(en)

1991-07-26

ATE119937T1
(en)

1995-04-15

IL80218A
(en)

1994-11-28

AU5465190A
(en)

1990-11-29

Similar Documents

Publication
Publication Date
Title

AU603775B2
(en)

1990-11-29

Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid

US5215893A
(en)

1993-06-01

Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid

US5089396A
(en)

1992-02-18

Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid

US4798885A
(en)

1989-01-17

Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain

EP0154434B1
(en)

1993-01-27

Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods

AU616672B2
(en)

1991-11-07

Growth hormone receptor

FI93025C
(en)

1995-02-10

Recombinant Lymphotoxin

AU623589B2
(en)

1992-05-21

Platelet related growth regulator

US5075224A
(en)

1991-12-24

Prepro-LHRH C-terminal peptide DNA

EP0178867B1
(en)

1994-01-12

Novel hormones and methods for making, using and assaying same

JPS63119679A
(en)

1988-05-24

Nucleic acid encoding alpha chain and beta chain of inhibin and synthesis of polypeptide using the same

IL108380A
(en)

1995-07-31

Human or porcine heterodimers of mature alpha and beta inhibin chains, dimers of mature beta inhibin chains and alpha or beta inhibin chain prodomain polypeptides

JP2713871B2
(en)

1998-02-16

Method for synthesizing human inhibin β ▲ A ▼ chain

EP0267272A1
(en)

1988-05-18

Atrial natriuretic peptide receptor protein and its encoding dna

WO1988009818A1
(en)

1988-12-15

Growth hormone receptor

IL104297A
(en)

1998-07-15

Lymphotoxin nucleic acid encoding it vectors incorporating the nucleic acid and cells transformed therewith and methods of obtaining lymphotoxin

NZ226980A
(en)

1991-07-26

Lymphotoxin-neutralising antibody and its use in separating out lymphotoxin from a composition

JPS61112100A
(en)

1986-05-30

Novel hormone, its production, use and analysis

Download PDF in English